<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Front Pharmacol</journal-id><journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id><journal-title-group><journal-title>Frontiers in Pharmacology</journal-title></journal-title-group><issn pub-type="epub">1663-9812</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7427466</article-id><article-id pub-id-type="doi">10.3389/fphar.2020.01189</article-id><article-categories><subj-group subj-group-type="heading"><subject>Pharmacology</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Medicinal Plants as Sources of Active Molecules Against COVID-19</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Benarba</surname><given-names>Bachir</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref><uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/877930"/></contrib><contrib contrib-type="author"><name><surname>Pandiella</surname><given-names>Atanasio</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/1016584"/></contrib></contrib-group><aff id="aff1">
<sup>1</sup>
<institution>Laboratory Research on Biological Systems and Geomatics, Faculty of Nature and Life Sciences, University of Mascara</institution>, <addr-line>Mascara</addr-line>, <country>Algeria</country>
</aff><aff id="aff2">
<sup>2</sup>
<institution>Instituto de Biolog&#x000ed;a Molecular y Celular del C&#x000e1;ncer, CSIC-IBSAL-Universidad de Salamanca</institution>, <addr-line>Salamanca</addr-line>, <country>Spain</country>
</aff><author-notes><fn fn-type="edited-by"><p>Edited by: Michael Heinrich, UCL School of Pharmacy, United Kingdom</p></fn><fn fn-type="edited-by"><p>Reviewed by: Ulrike Grienke, University of Vienna, Austria; Verena Spiegler, University of M&#x000fc;nster, Germany</p></fn><corresp id="fn001">*Correspondence: Bachir Benarba, <email xlink:href="mailto:bachirsb@yahoo.fr" xlink:type="simple">bachirsb@yahoo.fr</email>
</corresp><fn fn-type="other" id="fn002"><p>This article was submitted to Ethnopharmacology, a section of the journal Frontiers in Pharmacology</p></fn></author-notes><pub-date pub-type="epub"><day>07</day><month>8</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="pmc-release"><day>07</day><month>8</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>11</volume><elocation-id>1189</elocation-id><history><date date-type="received"><day>15</day><month>5</month><year>2020</year></date><date date-type="accepted"><day>22</day><month>7</month><year>2020</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2020 Benarba and Pandiella</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Benarba and Pandiella</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>The Severe Acute Respiratory Syndrome-related Coronavirus 2 (SARS-CoV-2) or novel coronavirus (COVID-19) infection has been declared world pandemic causing a worrisome number of deaths, especially among vulnerable citizens, in 209 countries around the world. Although several therapeutic molecules are being tested, no effective vaccines or specific treatments have been developed. Since the COVID-19 outbreak, different traditional herbal medicines with promising results have been used alone or in combination with conventional drugs to treat infected patients. Here, we review the recent findings regarding the use of natural products to prevent or treat COVID-19 infection. Furthermore, the mechanisms responsible for this preventive or therapeutic effect are discussed. We conducted literature research using PubMed, Google Scholar, Scopus, and WHO website. Dissertations and theses were not considered. Only the situation reports edited by the WHO were included. The different herbal products (extracts) and purified molecules may exert their anti-SARS-CoV-2 actions by direct inhibition of the virus replication or entry. Interestingly, some products may block the ACE-2 receptor or the serine protease TMPRRS2 required by SARS-CoV-2 to infect human cells. In addition, natural products were shown to inhibit the SARS-CoV-2 life-cycle related proteins such as papain-like or chymotrypsin-like proteases. In conclusion, we suggest that natural products could be used alone or in combination as alternative medicines to treat/prevent COVID-19 infection. Moreover, their structures may offer clues for the development of anti-SARS-CoV-2 drugs.</p></abstract><kwd-group><kwd>Severe Acute Respiratory Syndrome-related Coronavirus 2 (SARS-CoV-2)</kwd><kwd>Coronavirus Disease 2019 (COVID-19)</kwd><kwd>plants</kwd><kwd>natural products</kwd><kwd>ACE2</kwd></kwd-group><funding-group><award-group><funding-source id="cn001">Frontiers Foundation<named-content content-type="fundref-id">10.13039/501100004905</named-content></funding-source></award-group></funding-group><counts><fig-count count="6"/><table-count count="2"/><equation-count count="0"/><ref-count count="109"/><page-count count="16"/><word-count count="7771"/></counts></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>The Severe Acute Respiratory Syndrome-related Coronavirus 2 or novel coronavirus (COVID-19) infection has been declared world pandemic resulting in thousands of deaths in 216 countries around the world. The disease appeared in late December 2019 in Wuhan (China) as a result of zoonotic transmission (<xref rid="B55" ref-type="bibr">Mackenzie and Smith, 2020</xref>). Actually, the Severe Acute Respiratory Syndrome-related Coronavirus 2 (SARS-CoV-2) was shown to share 96% of the genomic identity with the related bat coronavirus (<xref rid="B108" ref-type="bibr">Zhou et&#x000a0;al., 2020</xref>). Moreover, the SARS-CoV-2 genome was found to be 91.02% identical to that of the Pangolin-CoV, raising the possibility that the latter acted as an intermediate zoonotic host between bats and humans (<xref rid="B105" ref-type="bibr">Zhang T. et&#x000a0;al., 2020</xref>). Till now, no vaccines or specific treatments for SARS-CoV-2 have been developed, although extraordinary efforts are being made (<xref rid="B2" ref-type="bibr">Amanat and Krammer, 2020</xref>). Some therapeutic approaches have been suggested such as nucleoside analogs, Remdesivir, anti-inflammatory drugs or Lopinavir/Ritonavir to treat COVID-19. At present, more than 200 clinical trials, some of them analyzing these drugs or others, have been registered in clinicaltrials.gov. Nevertheless, the clinical usefulness of these drugs against COVID-19 infection remains unclear (<xref rid="B47" ref-type="bibr">Li et&#x000a0;al., 2020</xref>).</p><p>Herbal traditional medicines have been used in China since the first days of the COVID-19 outbreak. Indeed, these traditional medicines were shown to result in the recovery of 90% of the 214 patients treated (<xref rid="B30" ref-type="bibr">Hong-Zhi et&#x000a0;al., 2020</xref>). Furthermore, some traditional herbal medicines prevented SARS-CoV-2 infection of healthy persons and improved the health state of patients with mild or severe symptoms (<xref rid="B30" ref-type="bibr">Hong-Zhi et&#x000a0;al., 2020</xref>). Similar promising results were reported in Zhejiang Province &#x02013; China (<xref rid="B96" ref-type="bibr">Xu K. et&#x000a0;al., 2020</xref>). Chinese traditional medicines known as Shu Feng Jie Du and Lianhuaqingwen have been recommended due to their demonstrated efficacy against previous influenza A (H1N1) or SARS-CoV-1 (<xref rid="B51" ref-type="bibr">Lu, 2020</xref>). A group of experts from the Zhongnan Hospital of Wuhan University included the use of traditional medicines in the guidelines for the treatment and prevention of COVID-19. Several methods using medicinal plants were recommended for the prevention of COVID-19. Moreover, to treat the disease, the experts recommended the use of different herbal mixtures according to the disease-stage (<xref rid="B34" ref-type="bibr">Jin et&#x000a0;al., 2020</xref>).</p><p>This review focuses on the possible uses of herbal traditional medicines and natural products in the prevention and treatment of COVID-19 infection (<xref rid="T1" ref-type="table">
<bold>Table 1</bold>
</xref>).</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Natural products tested against coronaviruses.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Plant (Family/part)</th><th valign="top" align="center" rowspan="1" colspan="1">Product</th><th valign="top" align="center" rowspan="1" colspan="1">Model/Strains</th><th valign="top" align="center" rowspan="1" colspan="1">Inhibitory assay</th><th valign="top" align="center" rowspan="1" colspan="1">Dosage/duration</th><th valign="top" align="center" rowspan="1" colspan="1">Control</th><th valign="top" align="center" rowspan="1" colspan="1">Effects</th><th valign="top" align="center" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Alnus japonica</italic> (Thunb.) Steud.<break/>(Betulaceae/bark)</td><td valign="top" align="left" rowspan="1" colspan="1">Hirsutenone<break/>(Ethanol extract)</td><td valign="top" align="left" rowspan="1" colspan="1">
<italic>In vitro</italic>
<break/>SARS-CoV- PLpro</td><td valign="top" align="left" rowspan="1" colspan="1">FRET</td><td valign="top" align="left" rowspan="1" colspan="1">0&#x02013;200 &#x000b5;M/60 min</td><td valign="top" align="left" rowspan="1" colspan="1">Curcumin (viral protease inhibitor)</td><td valign="top" align="left" rowspan="1" colspan="1">A dose-dependent inhibition of the SARS-CoV- PLpro activity (IC<sub>50</sub> = 4.1 &#x000b1; 0.3 &#x000b5;M while that of curcumin was 5.7 &#x000b1; 0.3 &#x000b5;M)</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B64" ref-type="bibr">Park et&#x000a0;al., 2012b</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Angelica keiskei</italic> (Miq.) Koidz<break/>(Umbelliferae/leaves)</td><td valign="top" align="left" rowspan="1" colspan="1">Xanthoangelol E<break/>(Ethanol extract)</td><td valign="top" align="left" rowspan="1" colspan="1">
<italic>In vitro</italic>
<break/>SARS-CoV- PLpro<break/>SARS-CoV- 3CL(pro)</td><td valign="top" align="left" rowspan="1" colspan="1">FRET<break/>Cell-based cis-cleavage inhibition assay</td><td valign="top" align="left" rowspan="1" colspan="1">0, 12.5, 25, 50 &#x000b5;M</td><td valign="top" align="left" rowspan="1" colspan="1">NS</td><td valign="top" align="left" rowspan="1" colspan="1">A dose-dependent inhibition of SARS-CoV- PLpro activity<break/>(IC<sub>50</sub> = 1.2 &#x000b1; 0.4 &#x000b5;M)<break/>A dose-dependent inhibition of SARS-CoV- 3CL(pro) activity (IC<sub>50</sub> = 11.4 &#x000b1; 1.4 &#x000b5;M)</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B67" ref-type="bibr">Park et&#x000a0;al., 2016</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Aglaia perviridis</italic> Hiern<break/>(Meliaceae/whole)</td><td valign="top" align="left" rowspan="1" colspan="1">Myricetin</td><td valign="top" align="left" rowspan="1" colspan="1">
<italic>In vitro</italic>
<break/>Angiotensin converting enzyme (ACE) from rabbit lung</td><td valign="top" align="left" rowspan="1" colspan="1">FRET</td><td valign="top" align="left" rowspan="1" colspan="1">0.01&#x02013;10 &#x000b5;M</td><td valign="top" align="left" rowspan="1" colspan="1">NS</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition of the SARS-CoV helicase by affecting the ATPase activity<break/>(IC<sub>50</sub> = 2.71&#x000a0;&#x000b1;&#x000a0;0.19&#x000a0;&#x003bc;M)</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B101" ref-type="bibr">Yu et&#x000a0;al., 2012</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Cibotium barometz</italic> (L.) J.Sm.<break/>(Dicksoniaceae/rhizomes)</td><td valign="top" align="left" rowspan="1" colspan="1">Ethanol and methanol extracts</td><td valign="top" align="left" rowspan="1" colspan="1">
<italic>In vitro</italic>
<break/>SARS-CoV virus propagated in Vero E6 cells</td><td valign="top" align="left" rowspan="1" colspan="1">Cytopathic effect inhibition<break/>ELISA<break/>FRET</td><td valign="top" align="left" rowspan="1" colspan="1">0, 25, 50, 100, and 200 &#x000b5;g/ml</td><td valign="top" align="left" rowspan="1" colspan="1">Vero E6 cells without extracts (negative control)<break/>SARS-CoV-infected Vero E6 cells (positive control)<break/>Valinomycin&#x000a0;(reference antiviral standard)</td><td valign="top" align="left" rowspan="1" colspan="1">Both extracts inhibited the SARS-CoV- replication at concentrations of 25 and 200 &#x003bc;g/ml.<break/>EC<sub>50</sub> were found to be 8.42 and &#x02265;10 &#x000b5;g/ml, respectively.</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B89" ref-type="bibr">Wen et&#x000a0;al., 2011</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Cullen corylifolium (L.) Medik.<break/>(Leguminosae/seeds)</td><td valign="top" align="left" rowspan="1" colspan="1">Psoralidin<break/>(Ethanol extract)</td><td valign="top" align="left" rowspan="1" colspan="1">
<italic>In vitro</italic>
<break/>SARS-CoV- PLpro</td><td valign="top" align="left" rowspan="1" colspan="1">Fluorogenic assay</td><td valign="top" align="left" rowspan="1" colspan="1">0&#x02013;100&#x000b5;M</td><td valign="top" align="left" rowspan="1" colspan="1">NS</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition of SARS-CoV PLpro in a dose-depenedent manner with IC<sub>50</sub> = 4.2 &#x000b1; 1.0 &#x000b5;M</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B40" ref-type="bibr">Kim et&#x000a0;al., 2014</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Ecklonia cava</italic>
<break/>(Laminariaceae/whole)</td><td valign="top" align="left" rowspan="1" colspan="1">Dieckol<break/>(Ethanol extract)</td><td valign="top" align="left" rowspan="1" colspan="1">
<italic>In vitro</italic>
<break/>SARS-CoV- 3CL(pro)</td><td valign="top" align="left" rowspan="1" colspan="1">FRET</td><td valign="top" align="left" rowspan="1" colspan="1">0&#x02013;200 &#x000b5;M</td><td valign="top" align="left" rowspan="1" colspan="1">Positive controls:<break/>hesperetin (60&#x000a0;&#x003bc;M),<break/>daidzein (105&#x000a0;&#x003bc;M), aloeemodin (132&#x000a0;&#x003bc;M)</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition of the SARS-CoV- 3CL(pro) activity<break/>(IC<sub>50</sub> = 2.7&#x000a0;&#x000b1;&#x000a0;0.6 &#x000b5;M)</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B66" ref-type="bibr">Park et&#x000a0;al., 2013</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Paulownia tomentosa</italic> (Thunb.) Steud.<break/>(Scrophulariaceae/fruits)</td><td valign="top" align="left" rowspan="1" colspan="1">Tomentin E<break/>(Methanol extract)</td><td valign="top" align="left" rowspan="1" colspan="1">
<italic>In vitro</italic>
<break/>SARS-CoV- PLpro</td><td valign="top" align="left" rowspan="1" colspan="1">Fluorogenic assay</td><td valign="top" align="left" rowspan="1" colspan="1">0, 6.25, 12.5, 25 &#x000b5;M</td><td valign="top" align="left" rowspan="1" colspan="1">NS</td><td valign="top" align="left" rowspan="1" colspan="1">A dose-dependent inhibition of SARS-CoV-PLpro (IC<sub>50</sub> = 5.0 &#x000b1; 0.06 &#x000b5;M)</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B9" ref-type="bibr">Cho et&#x000a0;al., 2013</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Quercus infectoria</italic>&#x000a0;G. Olivier<break/>(Fagaceae/bark)</td><td valign="top" align="left" rowspan="1" colspan="1">Ethanol-water extract</td><td valign="top" align="left" rowspan="1" colspan="1">
<italic>In vitro</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">Reverse phase high performance liquid chromatography (RP-HPLC)</td><td valign="top" align="left" rowspan="1" colspan="1">330 &#x000b5;g/ml</td><td valign="top" align="left" rowspan="1" colspan="1">Methanol solution (negative control)</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition of ACE activity by 93.9&#x02009;&#x000b1;&#x02009;2.5%</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B76" ref-type="bibr">Sharifi et&#x000a0;al., 2013</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Rheum</italic> sp.<break/>
<italic>Polygonum</italic> sp.<break/>(Polygonaceae/whole)</td><td valign="top" align="left" rowspan="1" colspan="1">Emodin</td><td valign="top" align="left" rowspan="1" colspan="1">
<italic>In vitro</italic>
<break/>Vero cells</td><td valign="top" align="left" rowspan="1" colspan="1">Luciferase assay</td><td valign="top" align="left" rowspan="1" colspan="1">0, 10, 50, 100, 200, and 400 &#x000b5;M</td><td valign="top" align="left" rowspan="1" colspan="1">NS</td><td valign="top" align="left" rowspan="1" colspan="1">Blockage of the binding SARS-CoV S protein and ACE2<break/>Minimal active concentration: 10 &#x000b5;M<break/>IC<sub>50</sub> = 200 &#x000b5;M</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B28" ref-type="bibr">Ho et&#x000a0;al., 2007</xref>
</td></tr><tr><td valign="top" rowspan="2" align="left" colspan="1">
<italic>Salvia miltiorrhiza</italic> Bunge<break/>(Lamiaceae/roots)</td><td valign="top" align="left" rowspan="1" colspan="1">Cryptotanshinone<break/>(n-hexane extract)</td><td valign="top" align="left" rowspan="1" colspan="1">
<italic>In vitro</italic>
<break/>SARS-CoV- PLpro</td><td valign="top" align="left" rowspan="1" colspan="1">FRET</td><td valign="top" align="left" rowspan="1" colspan="1">0&#x02013;200 &#x000b5;M/30 min</td><td valign="top" align="left" rowspan="1" colspan="1">NS</td><td valign="top" align="left" rowspan="1" colspan="1">A dose- and time-dependent inhibition of the SARS-CoV- PLpro activity in a slow-binding inhibition mechanism<break/>(IC<sub>50</sub> = 0.8&#x000a0;&#x000b1;&#x000a0;0.2 &#x000b5;M)</td><td valign="top" rowspan="2" align="left" colspan="1">
<xref rid="B63" ref-type="bibr">Park et&#x000a0;al., 2012a</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Dihydrotanshinone I<break/>(n-hexane extract)</td><td valign="top" align="left" rowspan="1" colspan="1">
<italic>In vitro</italic>
<break/>SARS-CoV- 3CL(pro)</td><td valign="top" align="left" rowspan="1" colspan="1">FRET</td><td valign="top" align="left" rowspan="1" colspan="1">0&#x02013;200 &#x000b5;M/60 min</td><td valign="top" align="left" rowspan="1" colspan="1">NS</td><td valign="top" align="left" rowspan="1" colspan="1">A dose-dependent but not time-dependent inhibition of the SARS-CoV- 3CL(pro) activity (IC<sub>50</sub> = 14.4&#x000a0;&#x000b1;&#x000a0;0.7 &#x000b5;M)</td></tr><tr><td valign="top" rowspan="4" align="left" colspan="1">
<italic>Sambucus javanica</italic> subsp. chinensis (Lindl.) Fukuoka<break/>(Adoxaceae/stem)</td><td valign="top" align="center" rowspan="1" colspan="1">95% ethanol extract</td><td valign="top" rowspan="4" align="left" colspan="1">
<italic>In vitro</italic>
<break/>HCoV-NL63 in LLC-MK2 cells</td><td valign="top" rowspan="4" align="left" colspan="1">Cytopathic effect inhibition</td><td valign="top" align="left" rowspan="1" colspan="1">0, 1, 10, and 50&#x000a0;&#x003bc;g/ml/36 h</td><td valign="top" rowspan="4" align="left" colspan="1">Virus-infection only with no test extract</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition of:<break/>-Viral cytopathicity<break/>(IC<sub>50</sub> = 1.17&#x000a0;&#x000b1;&#x000a0;0.75&#x000a0;&#x003bc;g/ml)<break/>-Virus attachment<break/>(IC<sub>50</sub> = 15.75&#x000a0;&#x000b1;&#x000a0;6.65&#x000a0;&#x003bc;g/mL)<break/>-Plaque formation<break/>4.67&#x000a0;&#x000b1;&#x000a0;1.21&#x000a0;&#x003bc;g/mL</td><td valign="top" rowspan="4" align="left" colspan="1">
<xref rid="B90" ref-type="bibr">Weng et&#x000a0;al., 2019</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Caffeic acid</td><td valign="top" rowspan="3" align="left" colspan="1">0, 10, 50, and 100&#x000a0;&#x003bc;M/36 h</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition of viral cytopathicity<break/>(IC<sub>50</sub> = 3.54&#x000a0;&#x000b1;&#x000a0;0.77&#x000a0;&#x003bc;M)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Chlorogenic acid</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition of viral cytopathicity<break/>(IC<sub>50</sub> = 43.45&#x000a0;&#x000b1;&#x000a0;6.01&#x000a0;&#x003bc;M)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Gallic acid</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition of viral cytopathicity<break/>(IC<sub>50</sub> = 71.48&#x000a0;&#x000b1;&#x000a0;18.40&#x000a0;&#x003bc;M)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Scutellaria&#x000a0;baicalensis&#x000a0;</italic>Georgi<break/>(Labiatae/whole)</td><td valign="top" align="left" rowspan="1" colspan="1">Scutellarein</td><td valign="top" align="left" rowspan="1" colspan="1">
<italic>In vitro</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">FRET</td><td valign="top" align="left" rowspan="1" colspan="1">0.01&#x02013;10 &#x000b5;M</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition of the SARS-CoV helicase by affecting the ATPase activity</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition of the SARS-CoV helicase by affecting the ATPase activity<break/>(IC<sub>50</sub> = 0.86 &#x000b1; 0.48 &#x000b5;M)</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B101" ref-type="bibr">Yu et&#x000a0;al., 2012</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Torreya nucifera</italic> (L.) Siebold &#x00026; Zucc.<break/>(Taxaceae/leaves)</td><td valign="top" align="left" rowspan="1" colspan="1">Amentoflavone<break/>(Ethanol extract)</td><td valign="top" align="left" rowspan="1" colspan="1">
<italic>In vitro</italic>
<break/>SARS-CoV- 3CL(pro)</td><td valign="top" align="left" rowspan="1" colspan="1">FRET</td><td valign="top" align="left" rowspan="1" colspan="1">0&#x02013;300 &#x000b5;M</td><td valign="top" align="left" rowspan="1" colspan="1">Positive controls:<break/>Apigenin (IC<sub>50</sub> = 280.8&#x000a0;&#x000b1;&#x000a0;21.4 &#x000b5;M)<break/>Luteolin (IC<sub>50</sub> = 20.0&#x000a0;&#x000b1;&#x000a0;2.2 &#x000b5;M)<break/>Quercetin (IC<sub>50</sub> = 23.8&#x000a0;&#x000b1;&#x000a0;1.9 &#x000b5;M)</td><td valign="top" align="left" rowspan="1" colspan="1">A dose-dependent inhibition of SARS-CoV- 3CL(pro) activity<break/>(IC<sub>50</sub> = 8.3 &#x000b1; 1.2 &#x000b5;M)</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B73" ref-type="bibr">Ryu et&#x000a0;al., 2010</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Tribulus terrestris</italic> L.<break/>(Zygophyllaceae/fruits)</td><td valign="top" align="left" rowspan="1" colspan="1">Terrestrimine<break/>(Methanol extract)</td><td valign="top" align="left" rowspan="1" colspan="1">
<italic>In vitro</italic>
<break/>SARS-CoV PLpro</td><td valign="top" align="left" rowspan="1" colspan="1">Fluorogenic assay</td><td valign="top" align="left" rowspan="1" colspan="1">1, 10, 100, 1,000 &#x000b5;M</td><td valign="top" align="left" rowspan="1" colspan="1">NS</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition of SARS-CoV - PLpro with<break/>IC<sub>50</sub> = 15.8 &#x000b1; 0.6 &#x000b5;M</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B81" ref-type="bibr">Song et&#x000a0;al., 2014</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;&#x02014;&#x02014;&#x02014;&#x02014;&#x02014;&#x02014;</td><td valign="top" align="left" rowspan="1" colspan="1">Lianhuaqingwen<break/>(Herbal mixture) dissolved in DMSO and then in serum-free DMEM</td><td valign="top" align="left" rowspan="1" colspan="1">
<italic>In vitro</italic>
<break/>SARS-CoV-2 virus propagated in Vero E6 cells</td><td valign="top" align="left" rowspan="1" colspan="1">Cytopathic effect inhibition</td><td valign="top" align="left" rowspan="1" colspan="1">0&#x02013;600 &#x000b5;g/ml/72 h</td><td valign="top" align="left" rowspan="1" colspan="1">Remdesivir (5 &#x000b5;M)</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition of the SARS-CoV-2 replication<break/>(IC<sub>50</sub> = 412.2 &#x000b5;g/ml <italic>vs</italic> 0.651 &#x000b5;M for the control)<break/>Inhibition of the plaque formation of the SARS-CoV-2<break/>Reduction of TNF-&#x003b1;, IL-6, CCL-2/MCP-1, and CXCL-10/IP-10 expression</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B72" ref-type="bibr">Runfeng et&#x000a0;al., 2020</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>&#x02014;&#x02014;&#x02014;&#x02014;&#x02014;&#x02014;&#x02013;</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">Herbacetin</td><td valign="top" align="left" rowspan="1" colspan="1">
<italic>In vitro</italic>
<break/>SARS-CoV- 3CL(pro)</td><td valign="top" align="left" rowspan="1" colspan="1">FRET</td><td valign="top" align="left" rowspan="1" colspan="1">1, 2.5, 20 &#x000b5;M/16 h</td><td valign="top" align="left" rowspan="1" colspan="1">NS</td><td valign="top" align="left" rowspan="1" colspan="1">A dose-dependent inhibition of SARS-CoV- 3CL(pro) activity<break/>(IC<sub>50</sub> = 33.17 &#x000b5;M)</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B35" ref-type="bibr">Jo et&#x000a0;al., 2020</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>&#x02014;&#x02014;&#x02014;&#x02014;&#x02014;&#x02014;&#x02013;</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">Pectolinarin</td><td valign="top" align="left" rowspan="1" colspan="1">
<italic>In vitro</italic>
<break/>SARS-CoV- 3CL(pro)</td><td valign="top" align="left" rowspan="1" colspan="1">FRET</td><td valign="top" align="left" rowspan="1" colspan="1">1, 2.5, 20 &#x000b5;M/16 h</td><td valign="top" align="left" rowspan="1" colspan="1">NS</td><td valign="top" align="left" rowspan="1" colspan="1">A dose-dependent inhibition of SARS-CoV- 3CL(pro) activity<break/>(IC<sub>50</sub> = 37.78&#x02009;&#x000b5;M)</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B35" ref-type="bibr">Jo et&#x000a0;al., 2020</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>&#x02014;&#x02014;&#x02014;&#x02014;&#x02014;&#x02014;&#x02013;</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">Rhoifolin</td><td valign="top" align="left" rowspan="1" colspan="1">
<italic>In vitro</italic>
<break/>SARS-CoV- 3CL(pro)</td><td valign="top" align="left" rowspan="1" colspan="1">FRET</td><td valign="top" align="left" rowspan="1" colspan="1">1, 2.5, 20 &#x000b5;M/16 h</td><td valign="top" align="left" rowspan="1" colspan="1">NS</td><td valign="top" align="left" rowspan="1" colspan="1">A dose-dependent inhibition of SARS-CoV- 3CL(pro) activity<break/>(IC<sub>50</sub> = 27.45 &#x000b5;M)</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B35" ref-type="bibr">Jo et&#x000a0;al., 2020</xref>
</td></tr></tbody></table><table-wrap-foot><fn><p>FRET, Fluorescence resonance energy transfer; GSEA, Microarray and Gene Set Enrichment Analysis; NS, Not specified.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2"><title>SARS-CoV-2</title><p>SARS-CoV-2 belongs to the&#x000a0;<italic>&#x003b2;</italic>&#x000a0;genus, Nidovirales order of the Coronaviridae family. SARS-CoV-2 is an enveloped, single (+) stranded RNA, with symmetric helical nucleocapsid (<xref rid="B38" ref-type="bibr">Khan et&#x000a0;al., 2020</xref>). The virus encodes twenty different proteins including four main structural proteins (S: spike; E: envelope; M: membrane; N: nucleocapsid), and several nonstructural proteins such as RNA-dependent RNA polymerase (RdRp), coronavirus main protease (3CLpro), and papain-like protease (PLpro) (<xref rid="B7" ref-type="bibr">Chen et&#x000a0;al., 2020</xref>).</p><p>The angiotensin converting enzyme II (ACE2) was found to be a key functional receptor for the SARS-CoV-2 allowing its attachment to human and bat cells and therefore its replication (<xref rid="B84" ref-type="bibr">Walls et&#x000a0;al., 2020</xref>; <xref rid="B108" ref-type="bibr">Zhou et&#x000a0;al., 2020</xref>). SARS-CoV-2 binds the host cells through interaction between the receptor binding motif of the spike protein&#x02014;receptor binding domain (RBD) and the ACE2 receptor. This interaction will trigger conformational changes of the C-terminal S2 subunit (responsible for virus-cell membrane fusion) of the spike protein. The complex S protein-ACE2 is then proteolytically processed by the host cell-type 2II transmembrane serine protease TMPRSS2 leading to the ACE2 cleavage and therefore to viral entry into the host cell (<xref rid="B33" ref-type="bibr">Jiang et&#x000a0;al., 2020</xref>; <xref rid="B71" ref-type="bibr">Rabi et&#x000a0;al., 2020</xref>). After entry and uncoating, the genomic RNA is translated into two polyproteins (pp1a and pp1ab) which undergo a proteolytic cleavage generating 15&#x02013;16 nonstructural proteins. The double-membrane vesicle is then formed from the rearrangement of cellular membrane induced by the nonstructural proteins. On the other hand, the genomic RNA is transcribed into subgenomic RNA which in turn leads to the synthesis of structural (spike, envelope, membrane, and nucleocapsid) and accessory proteins. Finally, virions are assembled in the ER-Golgi intermediate complex, and then released <italic>via</italic> the secretory pathway (<xref rid="B20" ref-type="bibr">Fung and Liu, 2020</xref>).</p><p>SARS-CoV-2 shares several genetic and clinical similarities with other coronaviruses of the <italic>&#x003b2;</italic>&#x000a0;genus such as SARs-CoV and NL63 (<xref rid="B18" ref-type="bibr">Fani et&#x000a0;al., 2020</xref>). Indeed, the entry of both viruses needs their interaction with the ACE2 receptor. However, some differences have been reported among these strains such as the length of the S protein and the structure of the receptor binding region (<xref rid="B5" ref-type="bibr">Ceccarelli et&#x000a0;al., 2020</xref>). On the other hand, a high nucleotides homology has been found between SARS-CoV-2 and SARS-CoV in addition to a high homology (95&#x02013;100%) that has been demonstrated between the proteins of the two strains. Actually, S2 and N proteins of SARS-CoV-2 and SARS-CoV share 99 and 90% similarities, respectively (<xref rid="B97" ref-type="bibr">Xu J. et&#x000a0;al., 2020</xref>).</p></sec><sec id="s3"><title>Natural Products With Anti-SARS-CoV-2 Effects</title><p>
<xref rid="B72" ref-type="bibr">Runfeng et&#x000a0;al. (2020)</xref> studied the inhibitory effects and anti-inflammatory potential of a Chinese herbal mixture called Lianhuaqingwen (a mixture of 11 medicinal species, a mineral medicine called gypsum and menthol) against SARS-CoV-2 (<xref rid="T2" ref-type="table">
<bold>Table 2</bold>
</xref>). Traditionally, Lianhuaqingwen has been widely used to treat fever, cough, fatigue, influenza, bronchitis, pneumonia, and early stage of measles (<xref rid="B15" ref-type="bibr">Ding et&#x000a0;al., 2017</xref>), and has been included in phase II clinical trial in the USA (<xref rid="B22" ref-type="bibr">Gao et&#x000a0;al., 2020</xref>). This herbal mixture was recommended by the Chinese National Health Commission to treat or manage COVID-19 (<xref rid="B99" ref-type="bibr">Yang Y. et&#x000a0;al., 2020</xref>). The anti-SARS-CoV-2 activity was assessed in Vero E6 cells using cytopathic effect inhibition and plaque reduction assays. The herbal mixture inhibited SARS-CoV-2 replication in a dose-dependent manner with an IC<sub>50</sub> of 411.2 &#x000b5;g/ml. Furthermore, the mixture was able to suppress the release of pro-inflammatory cytokines (TNF-&#x003b1;, IL-6, CCL-2/MCP-1, and CXCL-10/IP-10) in a dose-dependent manner (<xref rid="B72" ref-type="bibr">Runfeng et&#x000a0;al., 2020</xref>). These results could be interesting since the cytokine storm has been shown to be one of the COVID-19 lethal complications. In a previous study, among the 61 molecules identified in this herbal mixture, seven (arctiin, forsythoside A, gallic acid, isoliquiritigenin, kaempferol, rutin, and secoxyloganin) exhibited important antiviral activities with IC<sub>50</sub> ranging from 4.9 &#x000b1; 0.1 (kaempferol) to 47.8 &#x000b1; 1.5 &#x000b5;M (secoxyloganin) (<xref rid="B86" ref-type="bibr">Wang et&#x000a0;al., 2016</xref>). <xref rid="B87" ref-type="bibr">Wang et&#x000a0;al. (2020)</xref> reported results in four COVID-19 patients treated using a combination of lopinavir/ritonavir (Kaletra<sup>&#x000ae;</sup>) and arbidol with capsules of Shufeng Jiedu (a Chinese traditional medicine). After treatment, three patients were found COVID-19 negative and experienced significant improvements of the symptoms. In another study on 132 patients with COVID-19 living in northeast Chongqing (China), the traditional Chinese medicine was applied in almost 92% of them. The study concluded that the best therapeutic approach was a combination of Kaletra and the traditional medicine (<xref rid="B85" ref-type="bibr">Wan et&#x000a0;al., 2020</xref>). Recently, <xref rid="B52" ref-type="bibr">Lung et&#x000a0;al. (2020)</xref> demonstrated that theaflavin could be used as an important anti-SARS-CoV-2 drug using <italic>in silico</italic> approaches. Indeed, theaflavin showed promising docking affinities in the catalytic pocket of the SARS-CoV-2 RNA-dependent RNA polymerase. Nevertheless, it is worthy to point out that their bioavailability could limit their use since they are not absorbed in relevant amounts and that the theaflavin skeleton was found to resist to the degradation by the microbiota (<xref rid="B69" ref-type="bibr">Pereira-Caro et&#x000a0;al., 2017</xref>). By searching single cohort studies undertaken regarding the efficacy of herbal medicines against SARS and H1N1 influenza viruses, it has been concluded that medicinal species, usually used as herbal formula, could be an interesting preventive approach for high-risk populations (medical staff and their families&#x02019; members, people living in COVID-19 outbreak areas, old populations). Six herbal species were found to be the most frequently used including <italic>Astragalus mongholicus&#x000a0;</italic>Bunge, <italic>Glycyrrhiza glabra</italic> L., <italic>Saposhnikovia divaricata (</italic>Turcz. ex Ledeb.) Schischk., <italic>Atractylodes lancea</italic> (Thunb.) DC., <italic>Atractylodes macrocephala</italic> Koidz., <italic>Lonicera japonica</italic> Thunb., and <italic>Forsythia suspensa</italic> (Thunb.) Vahl. These species are the ingredients of the Chinese traditional medicine Yupingfeng powder (<xref rid="B53" ref-type="bibr">Luo et&#x000a0;al., 2020</xref>). On the other hand, the ethanol extract of <italic>Sambucus javanica</italic> subsp. chinensis (Lindl.) Fukuoka stem exerted promising anti-human coronavirus NL63 effects with IC<sub>50</sub> ranging from 1.17 (virus yield) to 15.75 &#x000b5;g/ml (virus attachment). The extract significantly decreased virus yield, plaque formation, and virus attachment. Furthermore, three of its major phenolic acids (caffeic, chlorogenic, and gallic acid) were shown to inhibit the NL63 replication and virus attachment. Caffeic acid was the most potent phenolic acid (<xref rid="B90" ref-type="bibr">Weng et&#x000a0;al., 2019</xref>). Phenolic acids are characterized by their metabolizing ability by the microbiota enhancing their bioavailability. Moreover, their antiviral potential could be increased with the alkyl chain length (<xref rid="B42" ref-type="bibr">Kumar and Goel, 2019</xref>). However, their efficacy is still controversial due to their low absorption and instability in alkaline and neutral media, which could limit their use in pure form. Therefore, the clinical utility of phenolic compounds as anti-SARS-CoV-2 agents remains debatable since their bioavailability, delivery mechanisms and efficient doses should be further studied using <italic>in vivo</italic> models.</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Traditional uses of the medicinal species and mixtures with possible anti-SARS-CoV-2 effects.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Plant (family)</th><th valign="top" align="center" rowspan="1" colspan="1">Traditional uses</th><th valign="top" align="center" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td valign="top" colspan="3" align="center" rowspan="1">
<bold>Medicinal species</bold>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Alnus japonica (Thunb.) Steud.</italic>
<break/>(Betulaceae)</td><td valign="top" align="left" rowspan="1" colspan="1">Cancer,<break/>Blood and lymphatic disorders,<break/>Gastroenteric disorders,<break/>Fever.</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B8" ref-type="bibr">Chi et&#x000a0;al., 2018</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Angelica keiskei</italic> (Miq.) Koidz. (Umbelliferae)</td><td valign="top" align="left" rowspan="1" colspan="1">Tonic,<break/>Galactagogue,<break/>Diuretic,<break/>Laxative,<break/>Analeptic.</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B39" ref-type="bibr">Kil et&#x000a0;al., 2017</xref>
<break/>
<xref rid="B16" ref-type="bibr">Du et&#x000a0;al., 2019</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Berberis integerrima</italic>&#x000a0;Bunge<break/>
<italic>(</italic>Berberidaceae<italic>)</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">Hypertension,<break/>Abdominal ache,<break/>Blood purification,<break/>Fever.</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B59" ref-type="bibr">Nasab and Khosravi, 2014</xref>
<break/>
<xref rid="B74" ref-type="bibr">Sadat-Hosseini et&#x000a0;al., 2017</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Cibotium barometz</italic> (L.) J. Sm.<break/>(Dicksoniaceae)</td><td valign="top" align="left" rowspan="1" colspan="1">Osteoporosis,<break/>Osteoarthritis,<break/>Inflammations,<break/>Rheumatism,<break/>Lumbago,<break/>Dysuria,<break/>Age-related leucorrhoea.</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B77" ref-type="bibr">Shi et&#x000a0;al., 2020</xref>
<break/>
<xref rid="B93" ref-type="bibr">Wu and Yang, 2009</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Crataegus laevigata</italic> (Poir.) DC.<break/>(Rosaceae)</td><td valign="top" align="left" rowspan="1" colspan="1">Hyperlipidemia,<break/>Arteriosclerosis,<break/>Hypertension,<break/>Cardiac disorders.</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B12" ref-type="bibr">&#x0010c;opra-Jani&#x00107;ijevi&#x00107; et&#x000a0;al., 2018</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Ecklonia cava</italic>
<break/>(Lessoniaceae)</td><td valign="top" align="left" rowspan="1" colspan="1">Inflammations,<break/>Asthma,<break/>Diabetes,<break/>Cancer.</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B10" ref-type="bibr">Cho et&#x000a0;al., 2020</xref>
<break/>
<xref rid="B103" ref-type="bibr">Yun et&#x000a0;al., 2018</xref>
<break/>
<xref rid="B65" ref-type="bibr">Park E. Y. et al., 2012</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Gentiana scabra</italic> Bunge<break/>(Gentianaceae)</td><td valign="top" align="left" rowspan="1" colspan="1">Inflammatory skin diseases,<break/>Gallbladder disorders,<break/>Jaundice,<break/>Leucorrhea.</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B98" ref-type="bibr">Yang et&#x000a0;al., 2019</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Onopordum acanthium</italic> L.<break/>(Asteraceae)</td><td valign="top" align="left" rowspan="1" colspan="1">Hypertension,<break/>Homeostasis,<break/>Bacterial infections.</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B76" ref-type="bibr">Sharifi et&#x000a0;al., 2013</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Paulownia tomentosa</italic> (Thunb.) Steud.<break/>(Scrophulariaceae)</td><td valign="top" align="left" rowspan="1" colspan="1">Bacterial and viral infections,<break/>Inflammations,<break/>Asthma,<break/>Hypertension,<break/>Hemorrhoids,<break/>Gonorrhea,<break/>Erysipelas.</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B32" ref-type="bibr">Ji et&#x000a0;al., 2015</xref>
<break/>
<xref rid="B43" ref-type="bibr">Lee et&#x000a0;al., 2018</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Cullen corylifolium</italic> (L.) Medik.<break/>(Leguminosae)</td><td valign="top" align="left" rowspan="1" colspan="1">Eczema,<break/>Osteoporosis,<break/>Colitis,<break/>Pollakiuria,<break/>Leukoderma,<break/>Asthma,<break/>Spermatorrhea,<break/>Bleeding.</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B96" ref-type="bibr">Xu et&#x000a0;al., 2020a</xref>
<break/>
<xref rid="B109" ref-type="bibr">Zhu et&#x000a0;al., 2019</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x000a0;<italic>Quercus infectoria</italic>&#x000a0;G. Olivier<break/>(Fagaceae)</td><td valign="top" align="left" rowspan="1" colspan="1">Diarrhea,<break/>Dysentery,<break/>Gonorrhea,<break/>Hemorrhages,<break/>Infections,<break/>Inflammations.</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B82" ref-type="bibr">Tayel et&#x000a0;al., 2018</xref>
<break/>
<xref rid="B11" ref-type="bibr">Chokpaisarn et&#x000a0;al. (2017)</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Salvia miltiorrhiza</italic> Bunge<break/>(Lamiaceae)</td><td valign="top" align="left" rowspan="1" colspan="1">Inflammations<break/>Cardiovascular and circulatory disorders,<break/>Menstrual disorders,<break/>Atherosclerosis,<break/>Cancer,<break/>Hyperglycemia.</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B88" ref-type="bibr">Wei et&#x000a0;al., 2020</xref>
<break/>
<xref rid="B48" ref-type="bibr">Liang et&#x000a0;al., 2020</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Sambucus javanica</italic> subsp. chinensis (Lindl.) Fukuoka<break/>(Adoxaceae)</td><td valign="top" align="left" rowspan="1" colspan="1">Bacterial infections,<break/>Inflammations,<break/>Liver disorders.</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B104" ref-type="bibr">Zhang et&#x000a0;al., 2010</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Senna tora&#x000a0;(L.) Roxb.<break/>(Fabaceae)</td><td valign="top" align="left" rowspan="1" colspan="1">Constipation,<break/>Liver disorders,<break/>Inflammations,<break/>Vision disorders.</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B44" ref-type="bibr">Lee et&#x000a0;al., 2019</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Taxillus chinensis</italic> (DC.) Danser (Loranthaceae)</td><td valign="top" align="left" rowspan="1" colspan="1">Liver and kidney disorders,<break/>Miscarriage,<break/>Rheumatic arthralgia,<break/>Metrorrhagia, Pregnancy-related Bleeding,<break/>Dizziness.</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B50" ref-type="bibr">Liu et&#x000a0;al., 2019</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Torreya nucifera</italic> (L.) Siebold &#x00026; Zucc.<break/>(Taxaceae)</td><td valign="top" align="left" rowspan="1" colspan="1">Stomachache,<break/>Hemorrhoids,<break/>Rheumatoid arthritis,<break/>Nervous disorders,<break/>Viral infections.</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B36" ref-type="bibr">Kalpana et&#x000a0;al., 2019</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Tribulus terrestris</italic> L.<break/>(Zygophyllaceae)</td><td valign="top" align="left" rowspan="1" colspan="1">Inflammation,<break/>Oxidative stress,<break/>Cancer,<break/>Cardiovascular disorders,<break/>Hormonal disorders,<break/>Muscle aches,<break/>Chest pain,<break/>Pruritus.</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B83" ref-type="bibr">Tian et&#x000a0;al., 2020</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Dioscorea polystachya</italic> Turcz. (Dioscoreaceae)</td><td valign="top" align="left" rowspan="1" colspan="1">Inflammations,<break/>Liver disorders,<break/>Diabetes,<break/>Hyperthyroidism,<break/>Digestive disorders,<break/>Cancer.</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B41" ref-type="bibr">Koo et&#x000a0;al., 2017</xref>
<break/>
<xref rid="B54" ref-type="bibr">Ma et&#x000a0;al., 2018</xref>
</td></tr><tr><td valign="top" colspan="3" align="left" rowspan="1">
<bold>Herbal mixtures</bold>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>Lianhuaqingwen</bold>
<break/>
<bold>Composition</bold>
<break/>Forsythiae Fructus [<italic>Forsythia suspensa</italic>&#x000a0;(Thunb.) Vahl], Lonicerae Japonicae Flos [<italic>Lonicera japonica</italic>&#x000a0;Thunb.], Ephedrae Herba (honey-fried) [<italic>Ephedra sinica Stapf</italic>,&#x000a0;<italic>Ephedra intermedia</italic>&#x000a0;Schrenk &#x00026; C. A. Mey. or&#x000a0;<italic>Ephedra equisetina</italic>&#x000a0;Bunge.], Armeniacae Semen Amarum (stir-baked) [<italic>Prunus armeniaca</italic>&#x000a0;L. var.&#x000a0;<italic>ansu</italic>&#x000a0;Maxim.,&#x000a0;<italic>Prunus sibirica</italic>&#x000a0;L.,&#x000a0;<italic>Prunus mandshurica</italic>&#x000a0;(Maxim.) Koehne or&#x000a0;<italic>Prunus armeniaca</italic>&#x000a0;L.], Gypsum Fibrosum, Isatidis Radix [<italic>Isatis tinctoria</italic>&#x000a0;L.], Dryopteris Crassirhizomatis Rhizoma [<italic>Dryopteris crassirhizoma</italic>&#x000a0;Nakai], Houttuyniae Herba [<italic>Houttuynia cordata</italic>&#x000a0;Thunb.], Pogostemonis Herba [<italic>Pogostemon cablin</italic>&#x000a0;(Blanco) Benth], Rhei Radix &#x00026; Rhizoma [<italic>Rheum palmatum</italic>&#x000a0;L.,&#x000a0;<italic>Rheum tanguticum</italic> (Maxim. ex Regel) Balf. or&#x000a0;<italic>Rheum officinale</italic>&#x000a0;Baill.], Rhodiolae Crenulatae Radix et Rhizoma [<italic>Rhodiola crenulata</italic> (Hook.f. &#x00026; Thomson) H.Ohba], menthol and Glycyrrhizae Radix et Rhizoma [<italic>Glycyrrhiza uralensis</italic> Fisch. ex DC.,&#x000a0;<italic>Glycyrrhiza inflata</italic> Batalin, or&#x000a0;<italic>Glycyrrhiza glabra</italic>&#x000a0;L.].</td><td valign="top" align="left" rowspan="1" colspan="1">Respiratory tract infectious diseases,<break/>Viral infections,<break/>Inflammations,<break/>Fever.</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B72" ref-type="bibr">Runfeng et&#x000a0;al., 2020</xref>
<break/>
<xref rid="B15" ref-type="bibr">Ding et&#x000a0;al., 2017</xref>
<break/>
<xref rid="B22" ref-type="bibr">Gao et&#x000a0;al., 2020</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>Shu Feng Jie Du</bold>
<break/>
<bold>Composition</bold>
<break/>Rhizoma Polygoni Cuspidati&#x000a0;[<italic>Reynoutria japonica</italic>&#x000a0;Houtt.]<break/>Fructus Forsythiae [<italic>Forsythia suspensa&#x000a0;</italic>(Thunb.) Vahl]<break/>Radix Isatidis [<italic>Isatis tinctoria</italic>&#x000a0;L.]<break/>Radix Bupleuri [<italic>Bupleurum chinense</italic>&#x000a0;DC.]<break/>Herba Patriniae [<italic>Patrinia scabiosifolia</italic>&#x000a0;Link]<break/>Herba Verbenae [<italic>Verbena officinalis</italic>&#x000a0;L.]<break/>Rhizoma Phragmitis [<italic>Phragmites australis</italic>&#x000a0;subsp. australis]<break/>Radix Glycyrrhizae [<italic>Glycyrrhiza uralensis</italic>&#x000a0;Fisch. ex DC.]</td><td valign="top" align="left" rowspan="1" colspan="1">Influenza,<break/>Viral infections,<break/>Immune regulation.</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B80" ref-type="bibr">Song et&#x000a0;al., 2013</xref>
<break/>
<xref rid="B99" ref-type="bibr">Yang Y. et&#x000a0;al. (2020)</xref>
<break/>
<xref rid="B94" ref-type="bibr">Xia et&#x000a0;al., 2020</xref>
</td></tr></tbody></table></table-wrap><p>
<xref rid="B89" ref-type="bibr">Wen et&#x000a0;al. (2011)</xref> evaluated 200 Chinese herbal extracts for their anti-SARS-CoV effect using a cell-based assay. Among them, six extracts [rhizomes of <italic>Gentiana scabra</italic> Bunge; tuber of <italic>Dioscorea polystachya</italic> Turcz.; seed of <italic>Senna tora</italic>&#x000a0;(L.) Roxb.; stem and leaves of <italic>Taxillus chinensis</italic> (DC.) Danser; and two extracts of <italic>Cibotium barometz</italic> (L.) J.Sm. rhizome] were found to significantly inhibit SARS-CoV growth and replication. IC<sub>50</sub> values ranged from 25 to 200 &#x003bc;g/ml. By using FRET assay, the study demonstrated that extracts obtained from tuber of <italic>Dioscorea polystachya</italic> Turcz. and rhizome of <italic>Cibotium barometz</italic> (L.) J.Sm. caused marked inhibition of SARS-CoV- 3CL protease with IC<sub>50</sub> of 39 and 44 &#x003bc;g/ml, respectively.</p><p>Owing to its importance as a key protein for SARS-CoV genome replication, SARS-CoV helicase still remains a target of novel antiviral drugs. Sixty-four natural molecules originated from 15 medicinal species were evaluated regarding their inhibitory activity of SARS-CoV helicase. Myricetin and scutellarein (<xref ref-type="fig" rid="f1">
<bold>Figure 1</bold>
</xref>) significantly inhibited the SARS-CoV helicase activity. At 10 &#x000b5;M, myricetin (IC<sub>50</sub> = 2.71 &#x000b1; 0.19 &#x000b5;M) and scutellarein (IC<sub>50</sub> = 0.86 &#x000b1; 0.48 &#x000b5;M) were able to inhibit 90% of the ATPase activity of the SARS-CoV helicase. Accordingly, Myricetin and scutellarein were suggested to be promising future anti-SARS drugs (<xref rid="B101" ref-type="bibr">Yu et&#x000a0;al., 2012</xref>).</p><fig id="f1" position="float"><label>Figure 1</label><caption><p>Natural products that act as SARS-CoV helicase activity.</p></caption><graphic xlink:href="fphar-11-01189-g001"/></fig><p>SARS-CoV-2 life-cycle related proteins are considered promising targets of antiviral drugs. Therefore, molecules and/or products able to inhibit these proteins may be used to treat or even prevent the SARS-CoV-2 infections (<xref rid="T1" ref-type="table">
<bold>Table 1</bold>
</xref>).</p></sec><sec id="s4"><title>Natural Products as ACE2-Blockers</title><p>The penetration of the SARS-CoV-2 genome into the host cells occurs as a result of the SARS-CoV-2 spike protein binding to host receptors (<xref rid="B78" ref-type="bibr">Sigrist et&#x000a0;al., 2020</xref>). By using phylogenetic analysis and critical site of ACE2 structure, different animals such as cat, pigeon, and sheep were predicted to be important intermediate hosts for SARS-CoV-2 (<xref rid="B70" ref-type="bibr">Qiu et&#x000a0;al., 2020</xref>). <xref rid="B29" ref-type="bibr">Hoffmann et&#x000a0;al. (2020)</xref> demonstrated that the ACE2 receptor is used by SARS-CoV-2 to enter human cells. Moreover, they reported that the use of TMPRSS2 inhibitors may be a promising therapeutic approach against SARS-CoV-2. TMPRSS2 is a transmembrane serine protease that cleaves both ACE2 and the S protein. Recently, <xref rid="B61" ref-type="bibr">Ortega et&#x000a0;al. (2020)</xref> used <italic>in silico</italic> approaches to understanding the relationship between changes in SARS-CoV-2 Spike protein and ACE2 receptor. They demonstrated superior affinity of SARS-CoV-2 spike protein towards human ACE2 as compared to that of the Bat-CoV spike and ACE2. This study supported the idea that the ACE2 receptor may be the key &#x0201c;bridge&#x0201d; used by SARS-CoV-2 to transmit among humans. <xref rid="B7" ref-type="bibr">Chen et&#x000a0;al. (2020)</xref> confirmed that although SARS-CoV and SARS-CoV-2 RBD of spike glycoprotein had 72% of structural similarities, SARS-CoV-2 RBD exhibited higher interaction with ACE2. ACE2 inhibitors are thought to indirectly alter the RBD binding site and therefore block SARS-CoV-2 infection. Likewise, <xref rid="B92" ref-type="bibr">Wrapp et&#x000a0;al. (2020)</xref> found that the SARS-CoV-2 spike exhibited a higher affinity to ACE2 than SARS-CoV. <xref rid="B1" ref-type="bibr">Adedeji et&#x000a0;al. (2013)</xref> demonstrated that early blocking of SARS-CoV with ACE2 inhibitors was one of the mechanisms used by novel efficient anti-SARS drugs. Nonetheless, it has been shown in three recent studies on COVID-19 that hypertension and diabetes mellitus significantly enhanced the risk of COVID-19 infection, in spite of using ACE2 inhibitors (<xref rid="B25" ref-type="bibr">Guan et&#x000a0;al., 2019</xref>; <xref rid="B100" ref-type="bibr">Yang X. et&#x000a0;al., 2020</xref>; <xref rid="B106" ref-type="bibr">Zhang J. J. et&#x000a0;al., 2020</xref>). ACE2 inhibitors, angiotensin II type-I receptor blockers, and ibuprofen lead to ACE2 upregulation which justifies the urgent need to use and/or identify alternative ACE2 blockers (<xref rid="B17" ref-type="bibr">Fang et&#x000a0;al., 2020</xref>). Hence, medicinal plants-derived products or natural products able to selectively block the ACE2 receptor without inhibiting the enzyme activity may be useful to prevent and/or treat SARS-CoV-2 spread in humans without increasing ACE2 expression in patients and therefore increased risk for COVID-19.</p><p>Since important similarities exist between the sequences of ACE and ACE2 (<xref rid="B26" ref-type="bibr">Guy et&#x000a0;al., 2005</xref>), molecules with inhibitory effects toward ACE may exert the same effect toward ACE2 and thus lead to reduce the viral entry. However, further studies should be undertaken to evaluate this hypothesis. <xref rid="B68" ref-type="bibr">Patten et&#x000a0;al. (2016)</xref> reviewed the medicinal plants for their inhibitory effects on ACE2. They reported 141 medicinal species belonging to 73 families and 49 purified natural compounds with documented ACE inhibitory potential. Moreover, 16 medicinal species (16 families) were found to be able to block the angiotensin type 1A receptor <italic>in vitro</italic>. <xref rid="B76" ref-type="bibr">Sharifi et&#x000a0;al. (2013)</xref> identified four Iranian medicinal species able to inhibit more than 80% of ACE activity <italic>in vitro</italic>. These active species were: <italic>Berberis integerrima</italic> Bunge., <italic>Crataegus laevigata</italic> (Poir.) DC.,&#x000a0;<italic>Onopordum acanthium</italic> L., and&#x000a0;<italic>Quercus infectoria</italic>&#x000a0;G. Olivier. At 330 &#x000b5;g/ml, Q<italic>uercus infectoria</italic>&#x000a0;G. Olivier. was found to be the most active and caused 94% ACE inhibition. This important inhibitory activity might be attributed to its higher phenolic content and enhanced antioxidant potential. In spite of the important ACE inhibition and antioxidant activities exhibited by <italic>Q. Infectoria</italic> extract, the presence of condensed tannins compromised its usefulness due to their interference in the functions of ACE. On the other hand, <italic>B. integerrima, C. microphylla</italic>&#x000a0;and&#x000a0;<italic>O. acanthium</italic> were found to have both important ACE inhibitory activities and enhanced antioxidant potential without the presence of tannins (<xref rid="B76" ref-type="bibr">Sharifi et&#x000a0;al., 2013</xref>
<italic>)</italic>. These species could be promising sources of antiviral molecules. Indeed, viral infections are accompanied by oxidative stress which in turn promotes virus replication. Antioxidant species decrease the ROS production in infected cells and target different oxidative stress-related signalling pathways resulting in reduction of viral spread (<xref rid="B19" ref-type="bibr">Fedoreyev et&#x000a0;al., 2018</xref>). <xref rid="B84" ref-type="bibr">Walls et&#x000a0;al. (2020)</xref> demonstrated that SARS-CoV-2 and SARS-CoV bind with similar affinities to ACE2. In another study, 25 Chinese herbal families were found to significantly inhibit the interaction SARS-CoV &#x02013; ACE2. Among them, species belonging to Polygonaceae, Labiatae, Oleaceae, Magnoliaceae, Lauraceae, and Nelumbonaceae exhibited the most important inhibitory effects. These inhibitory effects were attributed to emodin (1,3,8-trihydroxy-6-methylanthraquinone) (<xref ref-type="fig" rid="f2">
<bold>Figure 2</bold>
</xref>) produced in high levels in in genus&#x000a0;Rheum&#x000a0;and&#x000a0;Polygonum. Emodin blocked the interaction SARS-CoV S protein and ACE2 in a dose-dependent manner with an IC<sub>50</sub> of 200 &#x000b5;M (<xref rid="B28" ref-type="bibr">Ho et&#x000a0;al., 2007</xref>).</p><fig id="f2" position="float"><label>Figure 2</label><caption><p>Natural products that act as inhibitors of ACE2.</p></caption><graphic xlink:href="fphar-11-01189-g002"/></fig></sec><sec id="s5"><title>Natural Products Targeting the TMPRSS2</title><p>The type II transmembrane serine-proteinase serine type 2 RSS2 type II transmembrane serine protease that cleaves the S spike proteins of SARS-CoV and MERS and ACE2 (<xref rid="B31" ref-type="bibr">Iwata-Yoshikawa et&#x000a0;al., 2019</xref>). Recently, <xref rid="B29" ref-type="bibr">Hoffmann et&#x000a0;al. (2020)</xref> demonstrated that besides using ACE2 receptor to enter the host cells, SARS-CoV-2 uses also TMPRSS2 for S protein priming. After the interaction between the S spike protein (SARS-CoV-2) and the ACE2 (host cell), the complex is cleaved by the TMPRSS2 to facilitate viral entry (<xref rid="B71" ref-type="bibr">Rabi et&#x000a0;al., 2020</xref>). <xref rid="B57" ref-type="bibr">Matsuyama et&#x000a0;al. (2020)</xref> found that an important TMPRSS2 expression in cells makes them highly susceptible to SARS-CoV-2. Since SARS-CoV-2 viral entry is conditioned by its binding to the ACE2 receptor, and the latter should be cleaved by the TMPRSS, finding agents able to suppress or downregulate the TMPRSS2 expression in human cells could represent a promising therapeutic or preventive approach (<xref rid="B75" ref-type="bibr">Schlagenhauf et&#x000a0;al., 2020</xref>). Several studies have demonstrated that natural products could downregulate or suppress TMPRSS2. It has been shown that kaempferol was able to inactivate TMPRSS2 expression by 49.14 and 79.48% at 5 and 15&#x02009;&#x003bc;M, respectively (<xref rid="B14" ref-type="bibr">Da et&#x000a0;al., 2019</xref>). Likewise, sulforaphane (an isothiocyanate) was found to downregulate the TMPRSS2 expression through the release and translocation of the Nrf2 (nuclear factor (erythroid-derived 2)-like 2) (<xref rid="B23" ref-type="bibr">Gibbs et&#x000a0;al., 2009</xref>; <xref rid="B58" ref-type="bibr">Meyer and Jaspers, 2015</xref>). <xref rid="B56" ref-type="bibr">Mamouni et&#x000a0;al. (2018)</xref> found that a standardized flavonoids formulation including luteolin, quercetin, and kaempferol significantly suppressed TMPRSS2 expression. In spite of the diverse biological effects attributed to the three flavonoids, this study has demonstrated that at low concentrations, they exhibited an important synergic effect. Nonetheless, the efficacy and safety of these compounds in COVID-19 patients is still unclear. Moreover, modes of administration, the health of the patients&#x02019; digestive system, and disease stage may limit the clinical usefulness of such formulations and compounds (<xref rid="B21" ref-type="bibr">Fuzimoto and Isidoro, 2020</xref>). <xref rid="B95" ref-type="bibr">Xu et&#x000a0;al. (2012)</xref> demonstrated that cryptotanshinone at 0.5 &#x000b5;M effectively exhibited anti-TMPRSS2 activity (<xref ref-type="fig" rid="f3">
<bold>Figure 3</bold>
</xref>).</p><fig id="f3" position="float"><label>Figure 3</label><caption><p>Natural products that act as inhibitors of TMPRSS2.</p></caption><graphic xlink:href="fphar-11-01189-g003"/></fig></sec><sec id="s6"><title>Natural Products Targeting the Papain-Like Proteinase (Plpro)</title><p>PLpro is one of the nonstructural proteins encoded by the SARS-CoV-2 genome. This protease is vital for virus replication since it contributes to the cleavage of viral polyproteins (PP1A and PP1AB) into effector proteins (<xref rid="B33" ref-type="bibr">Jiang et&#x000a0;al., 2020</xref>). Moreover, PLpro has been found to be an antagonist of the host&#x02019;s innate immunity (<xref rid="B102" ref-type="bibr">Yuan et&#x000a0;al., 2015</xref>; <xref rid="B45" ref-type="bibr">Li et&#x000a0;al., 2016</xref>). Actually, PLpro was shown to target the interferon production by blocking the IRF3 phosphorylation, dimerization, and nuclear translocation and NF-&#x003ba;B signaling pathways (by preventing I&#x003ba;B&#x003b1; degradation) (<xref rid="B91" ref-type="bibr">Wong et&#x000a0;al., 2016</xref>). These effects were shown to occur in Toll-like receptor 3 and retinoic acid-inducible gene 1 pathways. Moreover, it has been demonstrated that SARS-CoV PLpro inhibits the TLR7 pathway <italic>via</italic> inactivation of TRAF3/6-TBK1-IRF3/NF-&#x003ba;B/AP1 signalling pathways (<xref rid="B102" ref-type="bibr">Yuan et&#x000a0;al., 2015</xref>).</p><p>Recently, <xref rid="B3" ref-type="bibr">Arya et&#x000a0;al. (2020)</xref> screened FDA-approved drugs for their <italic>in silico</italic> inhibitory potential of PLpro. They demonstrated that sixteen FDA-approved drugs (Biltricide, Cinacalcet, Procainamide, Terbinafine, Pethidine, Labetalol, Tetrahydrozoline, Ticlopidine, Ethoheptazine, Levamisole, Amitriptyline, Naphazoline, Formoterol, Benzylpenicillin, Chloroquine, and Chlorothiazide) exhibited important binding affinity to SARS-CoV-2 PLpro suggesting their possible effectiveness as anti-SARS-CoV-2 agents. Likewise, Disulfiram (an alcohol-aversive drug) was found to be a competitive inhibitor of SARS-CoV PLpro (<xref rid="B49" ref-type="bibr">Lin et&#x000a0;al., 2018</xref>).</p><p>Several compounds have been shown to target the SARS-CoV PLpro (<xref ref-type="fig" rid="f4">
<bold>Figure 4</bold>
</xref>).</p><fig id="f4" position="float"><label>Figure 4</label><caption><p>Natural products that act as inhibitors of PLpro.</p></caption><graphic xlink:href="fphar-11-01189-g004"/></fig><sec id="s6_1"><title>Cinnamic Amides From <italic>Tribulus terrestris</italic>
</title><p>Several natural compounds were found to possess promising PLpro inhibitory effects. Indeed, <xref rid="B81" ref-type="bibr">Song et&#x000a0;al. (2014)</xref> demonstrated that six cinnamic amides (N-trans-Feruloyloctopamine, N-trans-Coumaroyltyramine, N-trans-Caffeoyltryamine, Terrestrimine, N-trans-Feruloyltryamine, and Terrestriamide) extracted from <italic>Tribulus terrestris</italic> L. fruits were able to inhibit SARS-CoV PLpro in a dose-dependent manner. PLpro inhibitory IC<sub>50</sub> of these compounds were found to be 15.8&#x02013;70.1 &#x000b5;M. Terrestrimine [(E)-N-(1-hydroxy-2-(4-hydroxyphenyl)-2- oxoethyl)-3-(4-hydroxy-3-methoxypheny) acrylamide] showed the best inhibitory activity of SARS-CoV PLpro with an IC<sub>50</sub> of 15.8 &#x000b1; 0.6 &#x000b5;M. The presence of a polar substituent (ketone or alcohol) on the methylene groups (C8&#x02019;and C7&#x02019;) was associated with enhanced inhibitory activity.</p></sec><sec id="s6_2"><title>Flavonoids From <italic>Cullen corylifolium</italic> (L.) Medik.</title><p>Ethanolic extract of <italic>Cullen corylifolium</italic> (L.) Medik. seeds showed an important inhibitory effect of SARS-CoV PLpro with an IC<sub>50</sub> of 15 &#x000b5;g/ml. Furthermore, six flavonoids present in the extract (Bavachinin, neobavaisoflavone, isobavachalcone,40 &#x02013;O-methylbavachalcone, psoralidin, and corylifol A) inhibited SARS-CoV PLpro activity in a dose-dependent manner with IC<sub>50</sub> estimated to be 4.2&#x02013;38.4 &#x000b5;M. The highest inhibitory effect was exerted by psoralidin (IC<sub>50</sub> = 4.2 &#x000b1; 1.0 &#x000b5;M) and isobavachalcone (IC<sub>50</sub> = 7.3 &#x000b1; 0.8 &#x000b5;M) (<xref rid="B40" ref-type="bibr">Kim et&#x000a0;al., 2014</xref>).</p></sec><sec id="s6_3"><title>Flavonoids From <italic>Paulownia tomentosa</italic> (Thunb.) Steud.</title><p>
<xref rid="B9" ref-type="bibr">Cho et&#x000a0;al. (2013)</xref> identified five new geranylated flavonones, tomentin A, tomentin B, tomentin C, tomentin D, tomentin E from the ethanolic extract of <italic>Paulownia tomentosa</italic> (Thunb.) Steud. fruits. These flavonoids besides seven other knowns resulted in significant inhibition of SARS-CoV PLpro in a dose-dependent manner with IC<sub>50</sub> of 5.0 and 14.4 &#x003bc;M. Tomentin E exhibited the highest inhibitory effect with an IC<sub>50</sub> of 5.0 &#x000b1; 0.06 &#x000b5;M. It has been found that molecules with 3,4-dihydro-2H-pyran moiety possessed higher inhibition. The <italic>P. tomentosa</italic> flavonoids were found to be reversible, mixed inhibitors.</p></sec><sec id="s6_4"><title>Chalcones From <italic>Angelica keiskei</italic> (Miq.) Koidz</title><p>
<xref rid="B67" ref-type="bibr">Park et&#x000a0;al. (2016)</xref> investigated the inhibitory potential of nine alkylated chalcones (isobavachalcone, 4-hydroxyderricin, xanthoangelol, xanthoangelol F, xanthoangelol D, xanthoangelol E, xanthoangelol B, xanthoangelol G, xanthokeistal A) and four coumarins extracted from the ethanolic extract of <italic>Angelica keiskei</italic> (Miq.) Koidz. The alkylated chalcones inhibited SARS-CoV PLpro in a significant dose-dependent manner with IC<sub>50</sub> ranging from 1.2 &#x000b1; 0.4 to 46.4 &#x000b1; 7.8 &#x000b5;M. On the other hand, the analyzed coumarins did not show a significant inhibitory effect toward SARS-CoV PLpro. Kinetic studies revealed that isobavachalcone was a mixed inhibitor whereas the other chalcones were noncompetitive. Interestingly, xanthoangelol E, an &#x02013;OOH substituted analogue, exhibited the most enhanced inhibitory effect (IC<sub>50</sub> = 1.2 &#x000b1; 0.4 &#x000b5;M), which was 40-fold higher when compared to other tested chalcones. This important inhibitory activity of xanthoangelol E was confirmed using <italic>in silico studies.</italic>
</p></sec><sec id="s6_5"><title>Tanshinones From <italic>Salvia miltiorrhiza</italic> Bunge</title><p>
<italic>Salvia miltiorrhiza</italic> Bunge ethanolic extract (30 &#x000b5;g/ml) caused 88% inhibition of SARS-CoV PLpro. Moreover, seven bioactive tanshinones (tanshinone IIA, tanshinone IIB, methyl tanshinonate, cryptotanshinone, tanshinone I, dihydrotanshinone I, and rosmariquinone) were identified from the n-hexane fraction. These tanshinones were evaluated with regard to inhibition of SARS-CoV PLpro activity using a fluorometric assay. Both molecules exhibited important inhibitory time-dependent activities with IC<sub>50</sub> of 0.8 to 30 &#x000b5;M. The dimethyl tetrahydronaphthalen structure was associated with enhanced inhibitory potential. The results obtained showed that cryptotanshinone was the most potent inhibitor of SARS-CoV PLpro with an IC<sub>50</sub> of 0.8 &#x000b1; 0.2 &#x000b5;M. Kinetic investigations demonstrated that rosmariquinone was a mixed-type inhibitor of SARS-CoV PLpro, whereas the other tanshinones were noncompetitive inhibitors (<xref rid="B63" ref-type="bibr">Park et&#x000a0;al., 2012a</xref>).</p></sec><sec id="s6_6"><title>Diarylheptanoids From <italic>Alnus japonica</italic> (Thunb.) Steud.</title><p>
<xref rid="B64" ref-type="bibr">Park et&#x000a0;al. (2012b)</xref> used activity-guided fractionation to identify nine diarylheptanoids (platyphyllenone, hirsutenone, platyphyllone, platyphyllonol-5-xylopyranoside, hirsutanonol, oregonin, rubranol, rubranoside B, and rubranoside A) from the ethanol extract of <italic>Alnus japonica (Thunb.) Steud.</italic> They evaluated their SARS-CoV PLpro inhibitory effect using a continuous fluorometric assay. The results showed that hirsutenone, hirsutanonol, oregonin, rubranol, rubranoside B, and rubranoside A exerted a significant dose-dependent inhibitory activity towards SARS-CoV PLpro with IC<sub>50</sub> ranging from 3 to 44.5 &#x000b5;M. Hirsutenone possessed the most potent inhibitory effect with IC<sub>50</sub> of 4.1 &#x000b1; 0.3 &#x000b5;M which was less important than that of the reference inhibitor curcumin (5.7 &#x000b5;M). The enhanced inhibitory potential of diarylheptanoids seems to be related to the presence of &#x003b1;,&#x003b2;-unsaturated carbonyl, and catechol groups.</p></sec></sec><sec id="s7"><title>Natural Products Targeting the Chymotrypsin-Like Protease [3CL(pro)]</title><p>3CL(pro) belongs to the 16 nonstructural proteins of the SARS-CoV-2. Since it plays an important role in the SARS-CoV-2 replication process polyproteins, 3CL(pro) is considered a potential therapeutic target for anti-COVID-19 drugs (<xref rid="B107" ref-type="bibr">Zhang L. et&#x000a0;al., 2020</xref>). Different natural compounds exhibited promising anti3CL(pro) activities (<xref ref-type="fig" rid="f5">
<bold>Figure 5</bold>
</xref>).</p><fig id="f5" position="float"><label>Figure 5</label><caption><p>Natural products that act as inhibitors of 3CL(pro).</p></caption><graphic xlink:href="fphar-11-01189-g005"/></fig><sec id="s7_1"><title>Alkylated Chalcones From <italic>Angelica keiskei</italic> (Miq.) Koidz</title><p>Inhibitory potential toward SARS-CoV- 3CL(pro) of alkylated chalcones and coumarins extracted from <italic>Angelica keiskei</italic> (Miq.) Koidz was investigated using a fluorescence resonance energy transfer (FRET) method. Except for coumarins, alkylated chalcones exhibited marked inhibitory effects in a dose-dependent fashion. IC<sub>50</sub> ranged from 11.4 &#x000b1; 1.4 to 129.8 &#x000b1; 10.3 &#x000b5;M. Moreover, xanthoangelol E (<xref ref-type="fig" rid="f5">
<bold>Figure 5</bold>
</xref>) was found to be the most potent SARS-CoV- 3CL(pro) inhibitor. Kinetic studies showed that both alkylated chalcones were competitive inhibitors (<xref rid="B67" ref-type="bibr">Park O. K. et&#x000a0;al., 2016</xref>). Since xanthoangelol E was also found to inhibit SARS-CoV- PLpro (<xref rid="B67" ref-type="bibr">Park O. K. et&#x000a0;al., 2016</xref>) it could be a promising candidate in the therapeutic approach against COVID-19.</p></sec><sec id="s7_2"><title>Phlorotannins From <italic>Ecklonia cava</italic> (Algae)</title><p>
<xref rid="B66" ref-type="bibr">Park et&#x000a0;al. (2013)</xref> isolated nine phlorotannins from the ethanolic extract of brown Alga <italic>Ecklonia cava</italic>. These phlorotannins were assessed regarding their inhibitory effects towards SARS-CoV- 3CL(pro) using a cell-free based assay. Eight phlorotannins (triphloretol A, eckol, dioxinodehydroeckol, 2-phloroeckol, 7-phloroeckol, fucodiphloroethol G, dieckol, and phlorofucofuroeckol A) were shown to be competitive inhibitors of SARS-CoV- 3CL(pro) in a dose dependent manner. IC<sub>50</sub> ranged from 2.7 &#x000b1; 0.6 (dieckol) to 164.7 &#x000b1; 10.8 &#x000b5;M (triphloretol A). Moreover, six phlorotannins (dioxinodehydroeckol, 2-phloroeckol, 7-phloroeckol, fucodiphloroethol G, dieckol, and phlorofucofuroeckol A) resulted in a significant micromolar dose-dependent inhibition of SARS-CoV-3CL(pro) cis-cleavage activity. Of the tested molecules, diekcol (possessing two eckol groups linked by a diphenyl ether) exhibited the best inhibitory effect of SARS-CoV-3CL(pro). Molecular docking studies corroborated this result since diekcol possessed the lowest binding energy (11.51 kcal/mol) towards SARS-CoV-3CL(pro). Diekcol was shown to form strong H bonds to the catalytic dyad (Cys145 and His41). Nevertheless, the bioavailability of phlorotannins and the inter-individual differences regarding their metabolization is still a substantial limitation to validate their usefulness. Gut microbiota composition seems to play a critical role in determining their health benefits (<xref rid="B13" ref-type="bibr">Corona et&#x000a0;al., 2016</xref>). Moreover, the complexity of their structures due to the diversity of structural linkages and the different structural and conformational isomers for the same molecular weight, in addition to the absence of analytical standards and the lack of clear relationship between their structure and bioactivity may be another limitation to their clinical use (<xref rid="B46" ref-type="bibr">Li et&#x000a0;al., 2017</xref>).</p></sec><sec id="s7_3"><title>Tanshinones From <italic>Salvia miltiorrhiza</italic> Bunge</title><p>
<xref rid="B62" ref-type="bibr">Park O. K. et&#x000a0;al. (2012)</xref> investigated the inhibitory potential of <italic>Salvia miltiorrhiza</italic> Bunge towards SARS-CoV-3CL(pro). They found that <italic>Salvia miltiorrhiza</italic> Bunge ethanolic extract (30 &#x000b5;g/ml) resulted in 60% inhibition of SARS-CoV-3CL(pro). Furthermore, they demonstrated that six tanshinones of the plant (lipophilic fraction) exerted marked inhibition of SARS-CoV-3CL(pro) in a dose- but not&#x02013;time- dependent manner. IC<sub>50</sub> was estimated at 14.4&#x02013;89.1 &#x000b5;M. Dihydrotanshinone I exhibited the most important inhibitory effect with an IC<sub>50</sub> of 14.4 &#x000b1; 0.7 &#x000b5;M. With regard to the kinetic mechanism of SARS-CoV-3CL(pro) inhibition, <italic>Salvia miltiorrhiza</italic> Bunge tanshinones were found to be noncompetitive inhibitors.</p></sec><sec id="s7_4"><title>Biflavonoids From <italic>Torreya nucifera</italic> (L.) Siebold &#x00026; Zucc.</title><p>Four biflavonoids (amentoflavone, bilobetin, ginkgetin, and sciadopitysin) were isolated from the ethanol extract of <italic>Torreya nucifera</italic> (L.) Siebold &#x00026; Zucc. leaves and evaluated for their SARS-CoV-3CL(pro) inhibitory effect by using a FRET method. All biflavonoids exhibited a marked inhibitory effect of SARS-CoV-3CL(pro) with IC<sub>50</sub> of 8.3&#x02013;72.3 &#x000b5;M. This inhibitory effect was stronger than that of eight diterpenoids isolated from the <italic>T. nucifera</italic> extract (IC<sub>50</sub>: 49.6&#x02013;283.5 &#x000b5;M). Amentoflavone exerted the most important inhibitory activity since it possessed the lowest IC<sub>50</sub> (8.3 &#x000b1; 1.2 &#x000b5;M). Moreover, its inhibitory potential was more important than that of apigenin (IC<sub>50</sub> = 280.8 &#x000b1; 21.4 &#x000b5;M), quercetin (IC<sub>50</sub> = 23.8 &#x000b1; 1.9 &#x000b5;M) and luteolin (IC<sub>50</sub> = 20.0 &#x000b1; 2.2 &#x000b5;M). Molecular docking demonstrated that amentoflavone showed a good affinity with SARS-CoV-3CL(pro) and formed strong hydrogen bonds. An apigenin moiety at position C-30 of flavones was suggested to be responsible for a better inhibitory effect (<xref rid="B73" ref-type="bibr">Ryu et&#x000a0;al., 2010</xref>).</p></sec><sec id="s7_5"><title>Flavonoids</title><p>Seven flavonoids (Quercetin, Puerarin, Daidzein, gallocatechin gallate, epigallocatechin gallate, epigallocatechin, ampelopsi) were evaluated for their inhibitory effects of SARS-CoV-3CL(pro) expressed in <italic>Pichia pastoris</italic> GS115. At 200 &#x000b5;M, gallocatechin gallate, epigallocatechin gallate, and quercetin were able to inhibit the SARS-CoV-3CL(pro) activity by 91, 85, and 82%, respectively. Gallocatechin gallate was found to be a competitive inhibitor of SARS-CoV-3CL(pro) with IC<sub>50</sub> of almost 47&#x000b5;M. Molecular docking studies confirmed the important inhibitory potential of gallocatechin gallate owing to the hydrophobic and H-bonds interaction formed with the active site of SARS-CoV-3CL(pro) (<xref rid="B60" ref-type="bibr">Nguyen et&#x000a0;al., 2012</xref>). Nonetheless, it is difficult to predict how these H-bonds may contribute to the biological functions of the supposed active molecules (<xref rid="B6" ref-type="bibr">Chen et&#x000a0;al., 2016</xref>). Furthermore, the strength of the H-bonds is not evaluated in this study which could limit the selectivity of the tested molecules since an important number of weak H-bonds often increase their affinity and therefore their interaction with off-target proteins.</p><p>
<xref rid="B35" ref-type="bibr">Jo et&#x000a0;al. (2020)</xref> evaluated the inhibitory effect of 64 flavonoids towards SARS-CoV-3CL(pro) using the FRET method. They found that at 20 &#x000b5;M, rhoifolin, herbacetin, and pectolinarin possessed the higher inhibitory effect, with IC50 values of 27.45, 33.17, and 37.78&#x02009;&#x003bc;M, respectively. In addition, molecular docking revealed that flavonoids possessed an important binding affinity for SARS-CoV-3CL(pro) owing to their hydrophobic aromatic rings and hydrophilic hydroxyl groups.</p><p>
<xref ref-type="fig" rid="f6">
<bold>Figure 6</bold>
</xref> summarizes the possible anti-SARS-CoV 2 actions of natural products.</p><fig id="f6" position="float"><label>Figure 6</label><caption><p>Summary of possible anti SARS-CoV 2 actions of natural products.</p></caption><graphic xlink:href="fphar-11-01189-g006"/></fig></sec></sec><sec id="s8"><title>Critical Considerations</title><p>In the present review, 15 <italic>in vitro</italic> studies were included. They were from Korea (9/15), Taiwan (3/15), China (2/15), and Iran (1/15). Most of the studies (10/15) were published between 2011 and 2018 whereas only two studies (<xref rid="B72" ref-type="bibr">Runfeng et&#x000a0;al., 2020</xref>; <xref rid="B35" ref-type="bibr">Jo et&#x000a0;al., 2020</xref>) were published in 2020 and one study (<xref rid="B90" ref-type="bibr">Weng et&#x000a0;al., 2019</xref>) in 2019. Of them, only one study (<xref rid="B72" ref-type="bibr">Runfeng et&#x000a0;al., 2020</xref>) investigated the antiviral activity against SARS-CoV-2, and another (<xref rid="B90" ref-type="bibr">Weng et&#x000a0;al., 2019</xref>) on the human coronavirus NL63, whereas the other studies were not cell-based. Three studies used plant extracts and one study (<xref rid="B72" ref-type="bibr">Runfeng et&#x000a0;al., 2020</xref>), a herbal mixture of 11 Chinese plants. Ethanol, methanol, and water were the solvents used to prepare the plant extracts included in these studies. Most of the studies were conducted with isolated natural compounds belonging to different phytochemical classes. Phenolic compounds were the most frequently reported.</p><p>When studies were analyzed using the best practice recommendations in phytopharmacological research (<xref rid="B27" ref-type="bibr">Heinrich et&#x000a0;al., 2020</xref>), several concerns were detected especially regarding reporting data and outcomes. A large number of natural products reported in this review such as phenolic acids, quercetin, or kaempferol belong to phytochemical classes known to possess a broad spectrum of biological activities both <italic>in vitro</italic> and <italic>in vivo</italic>. Therefore, most of the studies failed to demonstrate the specificity of such products. In addition, all the included studies did not consider the drugability of the &#x0201c;active&#x0201d; compounds or extracts and presented an insufficient interpretation of the obtained data. Likewise, all the studies presented limitations regarding concepts and methods and also in the development of the project. In fact, all the studies investigating herbal extracts and isolated compounds did not consider the sustainable sourcing of the species nor the registration standards of both compounds or accepted plants&#x02019; names. Likewise, the included studies presented serious bias concerning the dose range and the toxic doses. On the other hand, eight studies did not report the use of control, whereas the other studies did not justify the choice of the positive controls used for comparison. This could be considered as a risk of bias resulting in possible limitations in the methodology of the studies. Besides, the lack of full taxonomic validity has been detected in all these studies.</p><p>It has been reported that IC<sub>50</sub> of chloroquine inhibition of SARS-CoV-2 replication was found to be 1.13 to 5.47 &#x000b5;M (<xref rid="B79" ref-type="bibr">Smit et&#x000a0;al., 2020</xref>) whereas that of SARS-CoV was 8.8 &#x000b5;M (<xref rid="B37" ref-type="bibr">Keyaerts et&#x000a0;al., 2004</xref>). On the other hand, IC<sub>50</sub> of ivermectin was found to be ~2&#x000a0;&#x003bc;M (<xref rid="B4" ref-type="bibr">Caly et&#x000a0;al., 2020</xref>). Therefore, molecules with IC<sub>50</sub> ranging from 0 to 10 &#x000b5;M have been considered as possible active molecules against SARS-CoV-2. Accordingly, few natural molecules reported in the included studies could be considered active against SARS-CoV-2 including amentoflavone, dieckol, hirsutenone, cryptotanshinone, xanthoangelol E, tomentin E, psoralidin, scutellarein, myricetin, and caffeic acid. Nevertheless, most of these active molecules are phenolic compounds characterized by a low bioavailability and rapid elimination (<xref rid="B24" ref-type="bibr">G&#x000f3;rniak et&#x000a0;al., 2019</xref>)&#x000a0;which could compromise their clinical usefulness in the context of COVID-19.</p><p>Despite the promising possible anti-SARS-CoV-2 effects exhibited by both plant extracts and natural molecules, several limitations should be considered. Overall, due to the recent outbreak, the clinical usefulness of these products needs to be demonstrated since the current data are still immature, and no final conclusions have been validated. As shown in <xref rid="T2" ref-type="table">
<bold>Table 2</bold>
</xref>, for some species, there was no relationship between the traditional ethnopharmacological uses and the anti-SARS-CoV-2 effects. In spite of that, these plants are currently used to treat or manage symptoms reported in SARS-CoV-2 disease such as fever, inflammations, or cardiovascular and circulatory disorders. Moreover, efficacy and safety of the active natural products should be further studied <italic>in vivo</italic> and clinically validated in COVID-19 patients. Importantly, bioavailability, modes of administration, safe doses, time of exposure, pharmacokinetic profile, the health of the patients&#x02019; digestive system, and disease stage are to be considered in the evaluation of the beneficial effects of natural products against SARS-CoV-2. On the other hand, further studies are needed to clarify the mechanisms and pathways targeted by such products, which will help to improve their clinical usefulness. Assessing the effects of combinations of active natural products with validated antiviral drugs could be a promising alternative to explore.</p></sec><sec id="s9"><title>Conclusion</title><p>Medicinal plants and natural products are still considered promising alternatives to prevent or treat several diseases. Since the outbreak of the COVID-19 pandemic in December 2019, various traditional herbal medicines have been used and resulted in positive health effects among COVID-19 patients, mainly in China. In the present review, we have discussed the possible potential uses of medicinal plants and/or natural products to prevent or even treat COVID-19. Although the studies evaluating the anti-SARS-CoV-2 effects of medicinal plants are still insufficient and relatively immature, some natural products with IC<sub>50</sub> below 10 &#x000b5;M could be considered as promising anti-SARS-CoV-2 agents since they were able to block its life-cycle related proteins such as the cellular receptor ACE2, papain-like or chymotrypsin-like proteinases. Nevertheless, several limitations have been detected in relation to the specificity of the action exerted by such products, sustainable sourcing of the species, doses range used, or the use of appropriate controls.</p><p>While available studies offer several indications that these plant-derived products may help in fighting COVID-19, further studies should be carried out to evaluate the clinical usefulness of such products against COVID-19 infection. Furthermore, the bioavailability of natural products with possible anti-SARS-CoV-2 effects such as tannins should be considered besides the need for clinical validation of their usefulness and safety. The herbal mixtures, medicinal plants, or natural products with possible anti-SARS-CoV-2 effects must be evaluated through prospective and interventional studies. A combination of natural products or herbal mixtures with validated anti-COVID-19 drugs may constitute a promising preventive and therapeutic alternative to be assessed.</p></sec><sec id="s10"><title>Author Contributions</title><p>BB and AP contributed equally to the study. All authors contributed to the article and approved the submitted version.</p></sec><sec id="s11"><title>Conflict of Interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></body><back><ack><title>Acknowledgments</title><p>We would like to thank the General Directorate&#x000a0;of&#x000a0;Scientific Research&#x000a0;and Technological Development&#x000a0;(DGRSDT &#x02013; Algeria).</p></ack><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Adedeji</surname><given-names>A. O.</given-names></name><name><surname>Severson</surname><given-names>W.</given-names></name><name><surname>Jonsson</surname><given-names>C.</given-names></name><name><surname>Singh</surname><given-names>K.</given-names></name><name><surname>Weiss</surname><given-names>S. R.</given-names></name><name><surname>Sarafianos</surname><given-names>S. G.</given-names></name></person-group> (<year>2013</year>). <article-title>Novel inhibitors of severe acute respiratory syndrome coronavirus entry that act by three distinct mechanisms</article-title>. <source>J. Virol.</source>
<volume>87</volume> (<issue>14</issue>), <fpage>8017</fpage>&#x02013;<lpage>8028</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.00998-13</pub-id>
<pub-id pub-id-type="pmid">23678171</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Amanat</surname><given-names>F.</given-names></name><name><surname>Krammer</surname><given-names>F.</given-names></name></person-group> (<year>2020</year>). <article-title>SARS-CoV-2vaccines: status report</article-title>. <source>J. Immunol.</source>
<volume>52</volume> (<issue>4</issue>), <fpage>583</fpage>&#x02013;<lpage>589</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2020.03.007</pub-id>
</mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Arya</surname><given-names>R.</given-names></name><name><surname>Das</surname><given-names>A.</given-names></name><name><surname>Prashar</surname><given-names>V.</given-names></name><name><surname>Kumar</surname><given-names>M.</given-names></name></person-group> (<year>2020</year>). <article-title>Potential inhibitors against papain-like protease of novel coronavirus (SARS-CoV-2) from FDA approved drugs</article-title>. <source>ChemRxiv.</source> &#x000a0;<pub-id pub-id-type="doi">10.26434/chemrxiv.11860011.v2</pub-id>
</mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Caly</surname><given-names>L.</given-names></name><name><surname>Druce</surname><given-names>J. D.</given-names></name><name><surname>Catton</surname><given-names>M. G.</given-names></name><name><surname>Jans</surname><given-names>D. A.</given-names></name><name><surname>Wagstaff</surname><given-names>K. M.</given-names></name></person-group> (<year>2020</year>). <article-title>The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro</article-title>. <source>Antivir. Res.</source>
<volume>178</volume>, <fpage>104787</fpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2020.104787</pub-id>
<pub-id pub-id-type="pmid">32251768</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ceccarelli</surname><given-names>M.</given-names></name><name><surname>Berretta</surname><given-names>M.</given-names></name><name><surname>Rullo</surname><given-names>E. V.</given-names></name><name><surname>Nunnari</surname><given-names>G.</given-names></name><name><surname>Cacopardo</surname><given-names>B.</given-names></name></person-group> (<year>2020</year>). <article-title>Editorial&#x02013;Differences and similarities between Severe Acute Respiratory Syndrome (SARS)-CoronaVirus (CoV) and SARS-CoV-2. Would a rose by another name smell as sweet</article-title>? <source>Eur. Rev. Med. Pharmacol. Sci.</source>
<volume>24</volume>, <fpage>2781</fpage>&#x02013;<lpage>2783</lpage>. <pub-id pub-id-type="doi">10.26355/eurrev_202003_20551</pub-id>
<pub-id pub-id-type="pmid">32196628</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>D.</given-names></name><name><surname>Oezguen</surname><given-names>N.</given-names></name><name><surname>Urvil</surname><given-names>P.</given-names></name><name><surname>Ferguson</surname><given-names>C.</given-names></name><name><surname>Dann</surname><given-names>S. M.</given-names></name><name><surname>Savidge</surname><given-names>T. C.</given-names></name></person-group> (<year>2016</year>). <article-title>Regulation of protein-ligand binding affinity by hydrogen bond pairing</article-title>. <source>Sci. Adv.</source>
<volume>2</volume> (<issue>3</issue>), <elocation-id>e1501240</elocation-id>. &#x000a0;<pub-id pub-id-type="doi">10.1126/sciadv.1501240</pub-id>
<pub-id pub-id-type="pmid">27051863</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Guo</surname><given-names>Y.</given-names></name><name><surname>Pan</surname><given-names>Y.</given-names></name><name><surname>Zhao</surname><given-names>Z. J.</given-names></name></person-group> (<year>2020</year>). <article-title>Structure analysis of the receptor binding of 2019-nCoV</article-title>. <source>Biochem. Biophys. Res. Commun.</source>
<volume>525</volume> (<issue>1</issue>), <fpage>135</fpage>&#x02013;<lpage>140</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2020.02.071</pub-id>
</mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chi</surname><given-names>J. H.</given-names></name><name><surname>Kim</surname><given-names>Y. H.</given-names></name><name><surname>Sohn</surname><given-names>D. H.</given-names></name><name><surname>Seo</surname><given-names>G. S.</given-names></name><name><surname>Lee</surname><given-names>S. H.</given-names></name></person-group> (<year>2018</year>). <article-title>Ameliorative effect of Alnus japonica ethanol extract on colitis through the inhibition of inflammatory responses and attenuation of intestinal barrier disruption in vivo and in vitro</article-title>. <source>BioMed. Pharmacother.</source>
<volume>108</volume>, <fpage>1767</fpage>&#x02013;<lpage>1774</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2018.10.050</pub-id>
<pub-id pub-id-type="pmid">30372880</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cho</surname><given-names>J. K.</given-names></name><name><surname>Curtis-Long</surname><given-names>M. J.</given-names></name><name><surname>Lee</surname><given-names>K. H.</given-names></name><name><surname>Kim</surname><given-names>D. W.</given-names></name><name><surname>Ryu</surname><given-names>H. W.</given-names></name><name><surname>Yuk</surname><given-names>H. J.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Geranylated flavonoids displaying SARS-CoV papain-like protease inhibition from the fruits of Paulownia tomentosa</article-title>. <source>Bioorg. Med. Chem.</source>
<volume>21</volume> (<issue>11</issue>), <fpage>3051</fpage>&#x02013;<lpage>3057</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmc.2013.03.027</pub-id>
<pub-id pub-id-type="pmid">23623680</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cho</surname><given-names>S. H.</given-names></name><name><surname>Kim</surname><given-names>H. S.</given-names></name><name><surname>Lee</surname><given-names>W.</given-names></name><name><surname>Han</surname><given-names>E. J.</given-names></name><name><surname>Kim</surname><given-names>S. Y.</given-names></name><name><surname>Fernando</surname><given-names>I. S.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Eckol from Ecklonia cava ameliorates TNF-&#x003b1;/IFN-&#x003b3;-induced inflammatory responses via regulating MAPKs and NF-&#x003ba;B signaling pathway in HaCaT cells</article-title>. <source>Int. Immunopharmacol.</source>
<volume>82</volume>, <fpage>106146</fpage>. <pub-id pub-id-type="doi">10.1016/j.intimp.2019.106146</pub-id>
<pub-id pub-id-type="pmid">32088638</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chokpaisarn</surname><given-names>J.</given-names></name><name><surname>Urao</surname><given-names>N.</given-names></name><name><surname>Voravuthikunchai</surname><given-names>S. P.</given-names></name><name><surname>Koh</surname><given-names>T. J.</given-names></name></person-group> (<year>2017</year>). <article-title>Quercus infectoria inhibits Set7/NF-&#x003ba;B inflammatory pathway in macrophages exposed to a diabetic environment</article-title>. <source>Cytokine</source>
<volume>94</volume>, <fpage>29</fpage>&#x02013;<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1016/j.cyto.2017.04.005</pub-id>
<pub-id pub-id-type="pmid">28408068</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>&#x0010c;opra-Jani&#x00107;ijevi&#x00107;</surname><given-names>A.</given-names></name><name><surname>&#x0010c;ulum</surname><given-names>D.</given-names></name><name><surname>Vidic</surname><given-names>D.</given-names></name><name><surname>Tahirovi&#x00107;</surname><given-names>A.</given-names></name><name><surname>Klepo</surname><given-names>L.</given-names></name><name><surname>Ba&#x00161;i&#x00107;</surname><given-names>N.</given-names></name></person-group> (<year>2018</year>). <article-title>Chemical composition and antioxidant activity of the endemic Crataegus microphylla Koch subsp. malyana KI Chr. &#x00026; Janji&#x00107; from Bosnia</article-title>. <source>Ind. Crops Prod.</source>
<volume>113</volume>, <fpage>75</fpage>&#x02013;<lpage>79</lpage>. <pub-id pub-id-type="doi">10.1016/j.indcrop.2018.01.016</pub-id>
</mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Corona</surname><given-names>G.</given-names></name><name><surname>Ji</surname><given-names>Y.</given-names></name><name><surname>Anegboonlap</surname><given-names>P.</given-names></name><name><surname>Hotchkiss</surname><given-names>S.</given-names></name><name><surname>Gill</surname><given-names>C.</given-names></name><name><surname>Yaqoob</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Gastrointestinal modifications and bioavailability of brown seaweed phlorotannins and effects on inflammatory markers</article-title>. <source>Br. J. Nutr.</source>
<volume>115</volume> (<issue>7</issue>), <fpage>1240</fpage>&#x02013;<lpage>1253</lpage>. <pub-id pub-id-type="doi">10.1017/S0007114516000210</pub-id>
<pub-id pub-id-type="pmid">26879487</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Da</surname><given-names>J.</given-names></name><name><surname>Xu</surname><given-names>M.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Lu</surname><given-names>M.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name></person-group> (<year>2019</year>). <article-title>Kaempferol Promotes Apoptosis While Inhibiting Cell Proliferation via Androgen-Dependent Pathway and Suppressing Vasculogenic Mimicry and Invasion in Prostate Cancer</article-title>. <source>Anal. Cell Pathol. (Amst)</source>
<volume>2019</volume>, <fpage>1907698</fpage>. <pub-id pub-id-type="doi">10.1155/2019/1907698</pub-id>
<pub-id pub-id-type="pmid">31871879</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ding</surname><given-names>Y.</given-names></name><name><surname>Zeng</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>R.</given-names></name><name><surname>Chen</surname><given-names>Q.</given-names></name><name><surname>Zhou</surname><given-names>B.</given-names></name><name><surname>Chen</surname><given-names>Q.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>The Chinese prescription lianhuaqingwen capsule exerts anti-influenza activity through the inhibition of viral propagation and impacts immune function</article-title>. <source>BMC Complement. Altern. Med.</source>
<volume>17</volume> (<issue>1</issue>), <fpage>130</fpage>. <pub-id pub-id-type="doi">10.1186/s12906-017-1585-7</pub-id>
<pub-id pub-id-type="pmid">28235408</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Du</surname><given-names>J.</given-names></name><name><surname>Hu</surname><given-names>Z.</given-names></name><name><surname>Dong</surname><given-names>W. J.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Wu</surname><given-names>S.</given-names></name><name><surname>Bai</surname><given-names>Y.</given-names></name></person-group> (<year>2019</year>). <article-title>Biosynthesis of large-sized silver nanoparticles using Angelica keiskei extract and its antibacterial activity and mechanisms investigation</article-title>. <source>Microchem. J.</source>
<volume>147</volume>, <fpage>333</fpage>&#x02013;<lpage>338</lpage>. <pub-id pub-id-type="doi">10.1016/j.microc.2019.03.046</pub-id>
</mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fang</surname><given-names>L.</given-names></name><name><surname>Karakiulakis</surname><given-names>G.</given-names></name><name><surname>Roth</surname><given-names>M.</given-names></name></person-group> (<year>2020</year>). <article-title>Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection</article-title>? <source>Lancet Respir. Med.</source>
<volume>8</volume> (<issue>4</issue>), <fpage>e21</fpage>. <pub-id pub-id-type="doi">10.1016/S2213-2600(20)30116-8</pub-id>
<pub-id pub-id-type="pmid">32171062</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fani</surname><given-names>M.</given-names></name><name><surname>Teimoori</surname><given-names>A.</given-names></name><name><surname>Ghafari</surname><given-names>S.</given-names></name></person-group> (<year>2020</year>). <article-title>Comparison of the COVID-2019 (SARS-CoV-2) pathogenesis with SARS-CoV and MERS-CoV infections</article-title>. <source>Future Virol.</source>
<volume>15</volume> (<issue>5</issue>), <fpage>317</fpage>&#x02013;<lpage>323</lpage>. &#x000a0;<pub-id pub-id-type="doi">10.2217/fvl-2020-0050</pub-id>
</mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fedoreyev</surname><given-names>S. A.</given-names></name><name><surname>Krylova</surname><given-names>N. V.</given-names></name><name><surname>Mishchenko</surname><given-names>N. P.</given-names></name><name><surname>Vasileva</surname><given-names>E. A.</given-names></name><name><surname>Pislyagin</surname><given-names>E. A.</given-names></name><name><surname>Iunikhina</surname><given-names>O. V.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Antiviral and Antioxidant Properties of Echinochrome A</article-title>. <source>Marine Drugs</source>
<volume>16</volume> (<issue>12</issue>), <fpage>509</fpage>. &#x000a0;<pub-id pub-id-type="doi">10.3390/md16120509</pub-id>
</mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fung</surname><given-names>T. S.</given-names></name><name><surname>Liu</surname><given-names>D. X.</given-names></name></person-group> (<year>2020</year>). <article-title>Human Coronavirus: Host-Pathogen Interaction</article-title>. <source>Annu. Rev. Microbiol.</source>
<volume>73</volume>, <fpage>529</fpage>&#x02013;<lpage>557</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-micro-020518-115759</pub-id>
</mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fuzimoto</surname><given-names>A. D.</given-names></name><name><surname>Isidoro</surname><given-names>C.</given-names></name></person-group> (<year>2020</year>). <article-title>The antiviral and coronavirus-host protein pathways inhibiting properties of herbs and natural compounds - Additional weapons in the fight against the COVID-19 pandemic</article-title>? <source>J. Trad. Complem. Med.</source>
<volume>10</volume> (<issue>4</issue>), <fpage>405</fpage>&#x02013;<lpage>419</lpage>. &#x000a0;<pub-id pub-id-type="doi">10.1016/j.jtcme.2020.05.003</pub-id>
</mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gao</surname><given-names>D.</given-names></name><name><surname>Niu</surname><given-names>M.</given-names></name><name><surname>Wei</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>C.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>Z.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Identification of a Pharmacological Biomarker for the Bioassay-Based Quality Control of a Thirteen-Component TCM Formula (Lianhua Qingwen) Used in Treating Influenza A Virus (H1N1) Infection</article-title>. <source>Front. Pharmacol.</source>
<volume>11</volume>, <elocation-id>746</elocation-id>. &#x000a0;<pub-id pub-id-type="doi">10.3389/fphar.2020.00746</pub-id>
<pub-id pub-id-type="pmid">32523531</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gibbs</surname><given-names>A.</given-names></name><name><surname>Schwartzman</surname><given-names>J.</given-names></name><name><surname>Deng</surname><given-names>V.</given-names></name><name><surname>Alumkal</surname><given-names>J.</given-names></name></person-group> (<year>2009</year>). <article-title>Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating histone deacetylase 6</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<volume>106</volume> (<issue>39</issue>), <fpage>16663</fpage>&#x02013;<lpage>16668</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0908908106</pub-id>
<pub-id pub-id-type="pmid">19805354</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>G&#x000f3;rniak</surname><given-names>I.</given-names></name><name><surname>Bartoszewski</surname><given-names>R.</given-names></name><name><surname>Kr&#x000f3;liczewski</surname><given-names>J.</given-names></name></person-group> (<year>2019</year>). <article-title>Comprehensive review of antimicrobial activities of plant flavonoids</article-title>. <source>Phytochem. Rev.</source>
<volume>18</volume>, <fpage>241</fpage>&#x02013;<lpage>272</lpage>. <pub-id pub-id-type="doi">10.1007/s11101-018-9591-z</pub-id>
</mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Guan</surname><given-names>W. J.</given-names></name><name><surname>Ni</surname><given-names>Z. Y.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Liang</surname><given-names>W. H.</given-names></name><name><surname>Ou</surname><given-names>C. Q.</given-names></name><name><surname>He</surname><given-names>J. X.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Clinical Characteristics of Coronavirus Disease 2019 in China</article-title>. <source>N. Engl. J. Med.</source>
<volume>382</volume> (<issue>18</issue>), <fpage>1708</fpage>&#x02013;<lpage>1720</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa2002032</pub-id>
</mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Guy</surname><given-names>J. L.</given-names></name><name><surname>Lambert</surname><given-names>D. W.</given-names></name><name><surname>Warner</surname><given-names>F. J.</given-names></name><name><surname>Hooper</surname><given-names>N. M.</given-names></name><name><surname>Turner</surname><given-names>A. J.</given-names></name></person-group> (<year>2005</year>). <article-title>Membrane-associated zinc peptidase families: comparing ACE and ACE2. <italic>Biochim Biophys Acta</italic> (BBA) -</article-title>. <source>Prot. Proteom.</source>
<volume>175</volume> (<issue>1</issue>), <fpage>2</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbapap.2004.10.010</pub-id>
</mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Heinrich</surname><given-names>M.</given-names></name><name><surname>Appendino</surname><given-names>G.</given-names></name><name><surname>Efferth</surname><given-names>T.</given-names></name><name><surname>F&#x000fc;rst</surname><given-names>R.</given-names></name><name><surname>Izzo</surname><given-names>A. A.</given-names></name><name><surname>Kayser</surname><given-names>O.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Best practice in research - Overcoming common challenges in phytopharmacological research</article-title>. <source>J. Ethnopharmacol.</source>
<volume>246</volume>, <fpage>112230</fpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2019.112230</pub-id>
<pub-id pub-id-type="pmid">31526860</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ho</surname><given-names>T. Y.</given-names></name><name><surname>Wu</surname><given-names>S. L.</given-names></name><name><surname>Chen</surname><given-names>J. C.</given-names></name><name><surname>Li</surname><given-names>C. C.</given-names></name><name><surname>Hsiang</surname><given-names>C. Y.</given-names></name></person-group> (<year>2007</year>). <article-title>Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction</article-title>. <source>Antivir. Res.</source>
<volume>74</volume> (<issue>2</issue>), <fpage>92</fpage>&#x02013;<lpage>101</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2006.04.014</pub-id>
<pub-id pub-id-type="pmid">16730806</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>M.</given-names></name><name><surname>Kleine-Weber</surname><given-names>H.</given-names></name><name><surname>Schroeder</surname><given-names>S.</given-names></name><name><surname>Kr&#x000fc;ger</surname><given-names>N.</given-names></name><name><surname>Herrler</surname><given-names>T.</given-names></name><name><surname>Erichsen</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor</article-title>. <source>Cell</source>
<volume>181</volume>, <fpage>1</fpage>&#x02013;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2020.02.052</pub-id>
<pub-id pub-id-type="pmid">32243785</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hong-Zhi</surname><given-names>D. U.</given-names></name><name><surname>Hou</surname><given-names>X. Y.</given-names></name><name><surname>Miao</surname><given-names>Y. H.</given-names></name><name><surname>Huang</surname><given-names>B. S.</given-names></name><name><surname>Liu</surname><given-names>D. H.</given-names></name></person-group> (<year>2020</year>). <article-title>Traditional Chinese Medicine: an effective treatment for 2019 novel coronavirus pneumonia (NCP)</article-title>. <source>Chin. J. Nat. Med.</source>
<volume>18</volume> (<issue>3</issue>), <fpage>226</fpage>&#x02013;<lpage>230</lpage>. <pub-id pub-id-type="doi">10.1016/S1875-5364(20)30022-4</pub-id>
<pub-id pub-id-type="pmid">32245593</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Iwata-Yoshikawa</surname><given-names>N.</given-names></name><name><surname>Okamura</surname><given-names>T.</given-names></name><name><surname>Shimizu</surname><given-names>Y.</given-names></name><name><surname>Hasegawa</surname><given-names>H.</given-names></name><name><surname>Takeda</surname><given-names>M.</given-names></name><name><surname>Nagata</surname><given-names>N.</given-names></name></person-group> (<year>2019</year>). <article-title>TMPRSS2 Contributes to Virus Spread and Immunopathology in the Airways of Murine Models after Coronavirus Infection</article-title>. <source>J. Virol.</source>
<volume>93</volume> (<issue>6</issue>), <fpage>e01815</fpage>&#x02013;<lpage>e01818</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.01815-18</pub-id>
<pub-id pub-id-type="pmid">30626688</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ji</surname><given-names>P.</given-names></name><name><surname>Chen</surname><given-names>C.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Zhan</surname><given-names>Z.</given-names></name><name><surname>Pan</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Antiviral activity of Paulownia tomentosa against enterovirus 71 of hand, foot, and mouth disease</article-title>. <source>Biol. Pharm. Bull.</source>
<volume>38</volume> (<issue>1</issue>), <fpage>1</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1248/bpb.b14-00357</pub-id>
<pub-id pub-id-type="pmid">25744451</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jiang</surname><given-names>S.</given-names></name><name><surname>Hillyer</surname><given-names>C.</given-names></name><name><surname>Du</surname><given-names>L.</given-names></name></person-group> (<year>2020</year>). <article-title>Neutralizing Antibodies against SARS-CoV-2and Other Human Coronaviruses</article-title>. <source>Trends Immunol.</source>
<volume>41</volume> (<issue>5</issue>), <fpage>355</fpage>&#x02013;<lpage>359</lpage>. <pub-id pub-id-type="doi">10.1016/j.it.2020.04.008</pub-id>
<pub-id pub-id-type="pmid">32249063</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jin</surname><given-names>Y. H.</given-names></name><name><surname>Cai</surname><given-names>L.</given-names></name><name><surname>Cheng</surname><given-names>Z. S.</given-names></name><name><surname>Cheng</surname><given-names>H.</given-names></name><name><surname>Deng</surname><given-names>T.</given-names></name><name><surname>Fan</surname><given-names>Y. P.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (COVID-19) infected pneumonia (standard version)</article-title>. <source>Mil. Med. Res.</source>
<volume>7</volume> (<issue>1</issue>), <fpage>4</fpage>. <pub-id pub-id-type="doi">10.1186/s40779-020-0233-6</pub-id>
<pub-id pub-id-type="pmid">32029004</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jo</surname><given-names>S.</given-names></name><name><surname>Kim</surname><given-names>S.</given-names></name><name><surname>Shin</surname><given-names>D. H.</given-names></name><name><surname>Kim</surname><given-names>M. S.</given-names></name></person-group> (<year>2020</year>). <article-title>Inhibition of SARS-CoV 3CL protease by flavonoids</article-title>. <source>J. Enzyme Inhib. Med. Chem.</source>
<volume>35</volume> (<issue>1</issue>), <fpage>145</fpage>&#x02013;<lpage>151</lpage>. <pub-id pub-id-type="doi">10.1080/14756366.2019.1690480</pub-id>
<pub-id pub-id-type="pmid">31724441</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kalpana</surname><given-names>D.</given-names></name><name><surname>Han</surname><given-names>J. H.</given-names></name><name><surname>Park</surname><given-names>W. S.</given-names></name><name><surname>Lee</surname><given-names>S. M.</given-names></name><name><surname>Wahab</surname><given-names>R.</given-names></name><name><surname>Lee</surname><given-names>Y. S.</given-names></name></person-group> (<year>2019</year>). <article-title>Green biosynthesis of silver nanoparticles using Torreya nucifera and their antibacterial activity</article-title>. <source>Arab. J. Chem.</source>
<volume>12</volume> (<issue>7</issue>), <fpage>1722</fpage>&#x02013;<lpage>1732</lpage>. <pub-id pub-id-type="doi">10.1016/j.arabjc.2014.08.016</pub-id>
</mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Keyaerts</surname><given-names>E.</given-names></name><name><surname>Vijgen</surname><given-names>L.</given-names></name><name><surname>Maes</surname><given-names>P.</given-names></name><name><surname>Neyts</surname><given-names>J.</given-names></name><name><surname>Van Ranst</surname><given-names>M.</given-names></name></person-group> (<year>2004</year>). <article-title>In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine</article-title>. <source>Biochem. Biophys. Res. Commun.</source>
<volume>323</volume> (<issue>1</issue>), <fpage>264</fpage>&#x02013;<lpage>268</lpage>. &#x000a0;<pub-id pub-id-type="doi">10.1016/j.bbrc.2004.08.085</pub-id>
<pub-id pub-id-type="pmid">15351731</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Khan</surname><given-names>S.</given-names></name><name><surname>Siddique</surname><given-names>R.</given-names></name><name><surname>Shereen</surname><given-names>M. A.</given-names></name><name><surname>Ali</surname><given-names>A.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Bai</surname><given-names>Q.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>The emergence of a novel coronavirus (SARS-CoV-2CoV-2), their biology and therapeutic options</article-title>. <source>J. Clin. Microbiol.</source>
<volume>58</volume> (<issue>5</issue>), <fpage>e00187</fpage>&#x02013;<lpage>e00120</lpage>. <pub-id pub-id-type="doi">10.1128/jcm.00187-20</pub-id>
<pub-id pub-id-type="pmid">32161092</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kil</surname><given-names>Y. S.</given-names></name><name><surname>Pham</surname><given-names>S. T.</given-names></name><name><surname>Seo</surname><given-names>E. K.</given-names></name><name><surname>Jafari</surname><given-names>M.</given-names></name></person-group> (<year>2017</year>). <article-title>Angelica keiskei, an emerging medicinal herb with various bioactive constituents and biological activities</article-title>. <source>Arch. Pharm. Res.</source>
<volume>40</volume> (<issue>6</issue>), <fpage>655</fpage>&#x02013;<lpage>675</lpage>. <pub-id pub-id-type="doi">10.1007/s12272-017-0892-3</pub-id>
<pub-id pub-id-type="pmid">28439780</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kim</surname><given-names>D. W.</given-names></name><name><surname>Seo</surname><given-names>K. H.</given-names></name><name><surname>Curtis-Long</surname><given-names>M. J.</given-names></name><name><surname>Oh</surname><given-names>K. Y.</given-names></name><name><surname>Oh</surname><given-names>J. W.</given-names></name><name><surname>Cho</surname><given-names>J. K.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Phenolic phytochemical displaying SARS-CoV papain-like protease inhibition from the seeds of Psoralea corylifolia</article-title>. <source>J. Enzyme Inhib. Med. Chem.</source>
<volume>29</volume> (<issue>1</issue>), <fpage>59</fpage>&#x02013;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.3109/14756366.2012.753591</pub-id>
<pub-id pub-id-type="pmid">23323951</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Koo</surname><given-names>H. J.</given-names></name><name><surname>Lee</surname><given-names>S.</given-names></name><name><surname>Chang</surname><given-names>K. J.</given-names></name><name><surname>Sohn</surname><given-names>E.</given-names></name><name><surname>Sohn</surname><given-names>E. H.</given-names></name><name><surname>Kang</surname><given-names>S. C.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Hepatic anti-inflammatory effect of hexane extracts of Dioscorea batatas Decne: Possible suppression of toll-like receptor 4-mediated signaling</article-title>. <source>BioMed. Pharmacother.</source>
<volume>92</volume>, <fpage>157</fpage>&#x02013;<lpage>167</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2017.05.036</pub-id>
<pub-id pub-id-type="pmid">28538192</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kumar</surname><given-names>N.</given-names></name><name><surname>Goel</surname><given-names>N.</given-names></name></person-group> (<year>2019</year>). <article-title>Phenolic acids: Natural versatile molecules with promising therapeutic applications</article-title>. <source>Biotechnol. Rep. (Amst)</source>
<volume>24</volume>, <fpage>e00370</fpage>. <pub-id pub-id-type="doi">10.1016/j.btre.2019.e00370</pub-id>
<pub-id pub-id-type="pmid">31516850</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lee</surname><given-names>J. W.</given-names></name><name><surname>Seo</surname><given-names>K. H.</given-names></name><name><surname>Ryu</surname><given-names>H. W.</given-names></name><name><surname>Yuk</surname><given-names>H. J.</given-names></name><name><surname>Park</surname><given-names>H. A.</given-names></name><name><surname>Lim</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Anti-inflammatory effect of stem bark of Paulownia tomentosa Steud. in lipopolysaccharide (LPS)-stimulated RAW264. 7 macrophages and LPS-induced murine model of acute lung injury</article-title>. <source>J. Ethnopharmacol.</source>
<volume>210</volume>, <fpage>23</fpage>&#x02013;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2017.08.028</pub-id>
<pub-id pub-id-type="pmid">28843892</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lee</surname><given-names>M. J.</given-names></name><name><surname>Nho</surname><given-names>J. H.</given-names></name><name><surname>Yang</surname><given-names>B. D.</given-names></name><name><surname>Park</surname><given-names>H.</given-names></name><name><surname>Lee</surname><given-names>H. J.</given-names></name><name><surname>Lee</surname><given-names>K. H.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Subchronic toxicity evaluation of ethanol extract of Cassia tora L. seeds in rats</article-title>. <source>Regulat. Toxicol. Pharmacol.</source>
<volume>109</volume>, <fpage>104487</fpage>. <pub-id pub-id-type="doi">10.1016/j.yrtph.2019.104487</pub-id>
</mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>S. W.</given-names></name><name><surname>Wang</surname><given-names>C. Y.</given-names></name><name><surname>Jou</surname><given-names>Y. J.</given-names></name><name><surname>Huang</surname><given-names>S. H.</given-names></name><name><surname>Hsiao</surname><given-names>L. H.</given-names></name><name><surname>Wan</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>SARS coronavirus papain-like protease inhibits the TLR7 signaling pathway through removing Lys63-linked polyubiquitination of TRAF3 and TRAF6</article-title>. <source>Int. J. Mol. Sci.</source>
<volume>17</volume> (<issue>5</issue>), <fpage>678</fpage>. <pub-id pub-id-type="doi">10.3390/ijms17050678</pub-id>
</mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Fu</surname><given-names>X.</given-names></name><name><surname>Duan</surname><given-names>D.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Gao</surname><given-names>X.</given-names></name></person-group> (<year>2017</year>). <article-title>Extraction and Identification of Phlorotannins from the Brown Alga, Sargassum fusiforme (Harvey) Setchell</article-title>. <source>Mar. Drugs</source>
<volume>15</volume> (<issue>2</issue>), <fpage>49</fpage>. <pub-id pub-id-type="doi">10.3390/md15020049</pub-id>
</mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>Y. M.</given-names></name><name><surname>Xu</surname><given-names>J. Y.</given-names></name><name><surname>Cao</surname><given-names>B.</given-names></name></person-group> (<year>2020</year>). <article-title>Potential Antiviral Therapeutics for 2019 Novel Coronavirus</article-title>. <source>Chin. J. Tuberc. Respir. Dis.</source>
<volume>43</volume> (<issue>3</issue>), <fpage>170</fpage>&#x02013;<lpage>172</lpage>. <pub-id pub-id-type="doi">10.3760/cma.j.issn.1001-0939.2020.03.004</pub-id>
</mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liang</surname><given-names>J.</given-names></name><name><surname>Yan</surname><given-names>C.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>T.</given-names></name><name><surname>Zheng</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name></person-group> (<year>2020</year>). <article-title>Rapid discrimination of Salvia miltiorrhiza according to their geographical regions by laser induced breakdown spectroscopy (LIBS) and particle swarm optimization-kernel extreme learning machine (PSO-KELM)</article-title>. <source>Chemometrics Intelligent Lab. Syst.</source>
<volume>197</volume>, <fpage>103930</fpage>. <pub-id pub-id-type="doi">10.1016/j.chemolab.2020.103930</pub-id>
</mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lin</surname><given-names>M. H.</given-names></name><name><surname>Moses</surname><given-names>D. C.</given-names></name><name><surname>Hsieh</surname><given-names>C. H.</given-names></name><name><surname>Cheng</surname><given-names>S. C.</given-names></name><name><surname>Chen</surname><given-names>Y. H.</given-names></name><name><surname>Sun</surname><given-names>C. Y.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Disulfiram can inhibit MERS and SARS coronavirus papain-like proteases via different modes</article-title>. <source>Antivir. Res.</source>
<volume>150</volume>, <fpage>155</fpage>&#x02013;<lpage>163</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2017.12.015</pub-id>
<pub-id pub-id-type="pmid">29289665</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>R.</given-names></name><name><surname>Su</surname><given-names>B.</given-names></name><name><surname>Huang</surname><given-names>F.</given-names></name><name><surname>Ru</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Qin</surname><given-names>Z.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Identification and analysis of cardiac glycosides in Loranthaceae parasites Taxillus chinensis (DC.) Danser and Scurrula parasitica Linn. and their host Nerium indicum Mill</article-title>. <source>J. Pharm. Biomedi. Anal.</source>
<volume>174</volume>, <fpage>450</fpage>&#x02013;<lpage>459</lpage>. <pub-id pub-id-type="doi">10.1016/j.jpba.2019.05.071</pub-id>
</mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lu</surname><given-names>H.</given-names></name></person-group> (<year>2020</year>). <article-title>Drug treatment options for the 2019-new coronavirus (COVID-19)</article-title>. <source>Biosci. Trends</source>
<volume>14</volume> (<issue>1</issue>), <fpage>69</fpage>&#x02013;<lpage>71</lpage>. <pub-id pub-id-type="doi">10.5582/bst.2020.01020</pub-id>
<pub-id pub-id-type="pmid">31996494</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lung</surname><given-names>J.</given-names></name><name><surname>Lin</surname><given-names>Y. S.</given-names></name><name><surname>Yang</surname><given-names>Y. H.</given-names></name><name><surname>Chou</surname><given-names>Y. L.</given-names></name><name><surname>Shu</surname><given-names>L. H.</given-names></name><name><surname>Cheng</surname><given-names>Y. C.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>The potential chemical structure of anti-SARS-CoV-2 RNA-dependent RNA polymerase</article-title>. <source>J. Med. Virol.</source>
<volume>10</volume>, <fpage>1002</fpage>. <pub-id pub-id-type="doi">10.1002/jmv.25761</pub-id>
</mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Luo</surname><given-names>H.</given-names></name><name><surname>Tang</surname><given-names>Q. L.</given-names></name><name><surname>Shang</surname><given-names>Y. X.</given-names></name><name><surname>Liang</surname><given-names>S. B.</given-names></name><name><surname>Yang</surname><given-names>M.</given-names></name><name><surname>Robinson</surname><given-names>N.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Can Chinese Medicine Be Used for Prevention of Corona Virus Disease 2019 (COVID-19)? A Review of Historical Classics, Research Evidence and Current Prevention Programs</article-title>. <source>Chin. J. Integr. Med.</source>
<volume>26</volume> (<issue>4</issue>), <fpage>243</fpage>&#x02013;<lpage>250</lpage>. <pub-id pub-id-type="doi">10.1007/s11655-020-3192-6</pub-id>
<pub-id pub-id-type="pmid">32065348</pub-id></mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ma</surname><given-names>J.</given-names></name><name><surname>Kang</surname><given-names>S. Y.</given-names></name><name><surname>Meng</surname><given-names>X.</given-names></name><name><surname>Kang</surname><given-names>A. N.</given-names></name><name><surname>Park</surname><given-names>J. H.</given-names></name><name><surname>Park</surname><given-names>Y. K.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Effects of rhizome extract of dioscorea batatas and its active compound, allantoin, on the regulation of myoblast differentiation and mitochondrial biogenesis in c2c12 myotubes</article-title>. <source>Molecules</source>
<volume>23</volume> (<issue>8</issue>), <fpage>2023</fpage>. <pub-id pub-id-type="doi">10.3390/molecules23082023</pub-id>
</mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mackenzie</surname><given-names>J. S.</given-names></name><name><surname>Smith</surname><given-names>D. W.</given-names></name></person-group> (<year>2020</year>). <article-title>COVID-19: a novel zoonotic disease caused by a coronavirus from China: what we know and what we don&#x02019;t</article-title>. <source>Microbiol. Aust.</source>
<volume>41</volume> (<issue>1</issue>), <fpage>45</fpage>&#x02013;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1071/MA20013</pub-id>
</mixed-citation></ref><ref id="B56"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mamouni</surname><given-names>K.</given-names></name><name><surname>Zhang</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Kim</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>A novel flavonoid composition targets androgen receptor signaling and inhibits prostate cancer growth in preclinical models</article-title>. <source>Neoplasia</source>
<volume>20</volume> (<issue>8</issue>), <fpage>789</fpage>&#x02013;<lpage>799</lpage>. <pub-id pub-id-type="doi">10.1016/j.neo.2018.06.003</pub-id>
<pub-id pub-id-type="pmid">29981500</pub-id></mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Matsuyama</surname><given-names>S.</given-names></name><name><surname>Nao</surname><given-names>N.</given-names></name><name><surname>Shirato</surname><given-names>K.</given-names></name><name><surname>Kawase</surname><given-names>M.</given-names></name><name><surname>Saito</surname><given-names>S.</given-names></name><name><surname>Takayama</surname><given-names>I.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<volume>117</volume> (<issue>13</issue>), <fpage>7001</fpage>&#x02013;<lpage>7003</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.2002589117</pub-id>
<pub-id pub-id-type="pmid">32165541</pub-id></mixed-citation></ref><ref id="B58"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Meyer</surname><given-names>M.</given-names></name><name><surname>Jaspers</surname><given-names>I.</given-names></name></person-group> (<year>2015</year>). <article-title>Respiratory protease/antiprotease balance determines susceptibility to viral infection and can be modified by nutritional antioxidants</article-title>. <source>Am. J. Physiol. Lung Cell Mol. Physiol.</source>
<volume>308</volume> (<issue>12</issue>), <fpage>1189</fpage>&#x02013;<lpage>1201</lpage>. <pub-id pub-id-type="doi">10.1152/ajplung.00028.2015</pub-id>
</mixed-citation></ref><ref id="B59"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nasab</surname><given-names>F. K.</given-names></name><name><surname>Khosravi</surname><given-names>A. R.</given-names></name></person-group> (<year>2014</year>). <article-title>Ethnobotanical study of medicinal plants of Sirjan in Kerman Province, Iran</article-title>. <source>J. Ethnopharmacol.</source>
<volume>154</volume> (<issue>1</issue>), <fpage>190</fpage>&#x02013;<lpage>197</lpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2014.04.003</pub-id>
<pub-id pub-id-type="pmid">24746480</pub-id></mixed-citation></ref><ref id="B60"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>T. T.</given-names></name><name><surname>Woo</surname><given-names>H. J.</given-names></name><name><surname>Kang</surname><given-names>H. K.</given-names></name><name><surname>Nguyen</surname><given-names>V. D.</given-names></name><name><surname>Kim</surname><given-names>Y. M.</given-names></name><name><surname>Kim</surname><given-names>D. W.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Flavonoid-mediated inhibition of SARS coronavirus 3C-like protease expressed in Pichia pastoris</article-title>. <source>Biotechnol. Lett.</source>
<volume>34</volume> (<issue>5</issue>), <fpage>831</fpage>&#x02013;<lpage>838</lpage>. <pub-id pub-id-type="doi">10.1007/s10529-011-0845-8</pub-id>
<pub-id pub-id-type="pmid">22350287</pub-id></mixed-citation></ref><ref id="B61"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ortega</surname><given-names>J. T.</given-names></name><name><surname>Serrano</surname><given-names>M. L.</given-names></name><name><surname>Pujol</surname><given-names>F. H.</given-names></name><name><surname>Rangel</surname><given-names>H. R.</given-names></name></person-group> (<year>2020</year>). <article-title>Role of changes in SARS-CoV-2 spike protein in the interaction with the human ACE2 receptor: An in silico analysis</article-title>. <source>Excli. J.</source>
<volume>19</volume>, <fpage>410</fpage>&#x02013;<lpage>417</lpage>. <pub-id pub-id-type="doi">10.17179/excli2020-1167</pub-id>
<pub-id pub-id-type="pmid">32210742</pub-id></mixed-citation></ref><ref id="B62"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Park</surname><given-names>O. K.</given-names></name><name><surname>Choi</surname><given-names>J. H.</given-names></name><name><surname>Park</surname><given-names>J. H.</given-names></name><name><surname>Kim</surname><given-names>I. H.</given-names></name><name><surname>Yan</surname><given-names>B. C.</given-names></name><name><surname>Ahn</surname><given-names>J. H.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Comparison of neuroprotective effects of five major lipophilic diterpenoids from Danshen extract against experimentally induced transient cerebral ischemic damage</article-title>. <source>Fitoterapia</source>
<volume>83</volume>, <fpage>1666</fpage>&#x02013;<lpage>1674</lpage>. <pub-id pub-id-type="doi">10.1016/j.fitote.2012.09.020</pub-id>
<pub-id pub-id-type="pmid">23022532</pub-id></mixed-citation></ref><ref id="B63"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Park</surname><given-names>J. Y.</given-names></name><name><surname>Kim</surname><given-names>J. H.</given-names></name><name><surname>Kim</surname><given-names>Y. M.</given-names></name><name><surname>Jeong</surname><given-names>H. J.</given-names></name><name><surname>Kim</surname><given-names>D. W.</given-names></name><name><surname>Park</surname><given-names>K. H.</given-names></name><etal/></person-group> (<year>2012</year>a). <article-title>Tanshinones as selective and slow-binding inhibitors for SARS-CoV cysteine proteases</article-title>. <source>Bioorg. Med. Chem.</source>
<volume>20</volume> (<issue>19</issue>), <fpage>5928</fpage>&#x02013;<lpage>5935</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmc.2012.07.038</pub-id>
<pub-id pub-id-type="pmid">22884354</pub-id></mixed-citation></ref><ref id="B64"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Park</surname><given-names>J. Y.</given-names></name><name><surname>Jeong</surname><given-names>H. J.</given-names></name><name><surname>Kim</surname><given-names>J. H.</given-names></name><name><surname>Kim</surname><given-names>Y. M.</given-names></name><name><surname>Park</surname><given-names>S. J.</given-names></name><name><surname>Kim</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2012</year>b). <article-title>Diarylheptanoids from Alnus japonica Inhibit Papain-Like Protease of Severe Acute Respiratory Syndrome Coronavirus</article-title>. <source>Bioorg. Med. Chem.</source>
<volume>5</volume> (<issue>11</issue>), <fpage>2036</fpage>&#x02013;<lpage>2042</lpage>. <pub-id pub-id-type="doi">10.1248/bpb.b12-00623</pub-id>
</mixed-citation></ref><ref id="B65"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Park</surname><given-names>E. Y.</given-names></name><name><surname>Kim</surname><given-names>E. H.</given-names></name><name><surname>Kim</surname><given-names>M. H.</given-names></name><name><surname>Seo</surname><given-names>Y. W.</given-names></name><name><surname>Lee</surname><given-names>J. I.</given-names></name><name><surname>Jun</surname><given-names>H. S.</given-names></name></person-group> (<year>2012</year>). <article-title>Polyphenol-rich fraction of brown alga Ecklonia cava collected from Gijang, Korea, reduces obesity and glucose levels in high-fat diet-induced obese mice</article-title>. <source>Evid. Based Complement. Alternat. Med.</source>
<volume>2012</volume>, <fpage>1</fpage>&#x02013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1155/2012/418912</pub-id>
</mixed-citation></ref><ref id="B66"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Park</surname><given-names>J. Y.</given-names></name><name><surname>Kim</surname><given-names>J. H.</given-names></name><name><surname>Kwon</surname><given-names>J. M.</given-names></name><name><surname>Kwon</surname><given-names>H. J.</given-names></name><name><surname>Jeong</surname><given-names>H. J.</given-names></name><name><surname>Kim</surname><given-names>Y. M.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Dieckol, a SARS-CoV 3CLpro inhibitor, isolated from the edible brown algae Ecklonia cava</article-title>. <source>Bioorg. Med. Chem.</source>
<volume>21</volume> (<issue>13</issue>), <fpage>3730</fpage>. <pub-id pub-id-type="doi">10.1016/j.bmc.2013.04.026</pub-id>
<pub-id pub-id-type="pmid">23647823</pub-id></mixed-citation></ref><ref id="B67"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Park</surname><given-names>J. Y.</given-names></name><name><surname>Ko</surname><given-names>J. A.</given-names></name><name><surname>Kim</surname><given-names>D. W.</given-names></name><name><surname>Kim</surname><given-names>Y. M.</given-names></name><name><surname>Kwon</surname><given-names>H. J.</given-names></name><name><surname>Jeong</surname><given-names>H. J.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Chalcones isolated from Angelica keiskei inhibit cysteine proteases of SARS-CoV</article-title>. <source>J. Enzyme Inhib. Med. Chem.</source>
<volume>31</volume> (<issue>1</issue>), <fpage>23</fpage>&#x02013;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.3109/14756366.2014.1003215</pub-id>
</mixed-citation></ref><ref id="B68"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Patten</surname><given-names>G. S.</given-names></name><name><surname>Abeywardena</surname><given-names>M. Y.</given-names></name><name><surname>Bennett</surname><given-names>L. E.</given-names></name></person-group> (<year>2016</year>). <article-title>Inhibition of Angiotensin Converting Enzyme, Angiotensin II Receptor Blocking, and Blood Pressure Lowering Bioactivity across Plant Families</article-title>. <source>Crit. Rev. Food Sci. Nutr.</source>
<volume>56</volume> (<issue>2</issue>), <fpage>181</fpage>&#x02013;<lpage>214</lpage>. <pub-id pub-id-type="doi">10.1080/10408398.2011.651176</pub-id>
<pub-id pub-id-type="pmid">24915402</pub-id></mixed-citation></ref><ref id="B69"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pereira-Caro</surname><given-names>G.</given-names></name><name><surname>Moreno-Rojas</surname><given-names>J. M.</given-names></name><name><surname>Brindani</surname><given-names>N.</given-names></name><name><surname>Del Rio</surname><given-names>D.</given-names></name><name><surname>Lean</surname><given-names>M. E.</given-names></name><name><surname>Hara</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Bioavailability of black tea theaflavins: Absorption, metabolism, and colonic catabolism</article-title>. <source>J. Agri. Food Chem.</source>
<volume>65</volume> (<issue>26</issue>), <fpage>5365</fpage>&#x02013;<lpage>5374</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jafc.7b01707</pub-id>
</mixed-citation></ref><ref id="B70"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Qiu</surname><given-names>Y.</given-names></name><name><surname>Zhao</surname><given-names>Y. B.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Li</surname><given-names>J. Y.</given-names></name><name><surname>Zhou</surname><given-names>Z. J.</given-names></name><name><surname>Liao</surname><given-names>C. H.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Predicting the angiotensin converting enzyme 2 (ACE2) utilizing capability as the receptor of SARSCoV-2</article-title>. <source>Microbes Infect.</source>
<volume>22</volume> (<issue>4&#x02013;5</issue>), <fpage>221</fpage>&#x02013;<lpage>225</lpage>. <pub-id pub-id-type="doi">10.1016/j.micinf.2020.03.003</pub-id>
<pub-id pub-id-type="pmid">32199943</pub-id></mixed-citation></ref><ref id="B71"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rabi</surname><given-names>F.</given-names></name><name><surname>Al Zoubi</surname><given-names>M. S.</given-names></name><name><surname>Kasasbeh</surname><given-names>G. A.</given-names></name><name><surname>Salameh</surname><given-names>D. M.</given-names></name><name><surname>Al-Nasser</surname><given-names>A. D.</given-names></name></person-group> (<year>2020</year>). <article-title>SARS-CoV-2CoV-2 and Coronavirus Disease 2019: What We Know So Far</article-title>. <source>Pathogens</source>
<volume>9</volume> (<issue>3</issue>), <fpage>231</fpage>. <pub-id pub-id-type="doi">10.3390/pathogens9030231</pub-id>
</mixed-citation></ref><ref id="B72"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Runfeng</surname><given-names>L.</given-names></name><name><surname>Yunlong</surname><given-names>H.</given-names></name><name><surname>Jicheng</surname><given-names>H.</given-names></name><name><surname>Weiqi</surname><given-names>P.</given-names></name><name><surname>Qinhai</surname><given-names>M.</given-names></name><name><surname>Yongxia</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2)</article-title>. <source>Pharmacol. Res.</source>
<volume>156</volume>, <fpage>104761</fpage>. <pub-id pub-id-type="doi">10.1016/j.phrs.2020.104761</pub-id>
<pub-id pub-id-type="pmid">32205232</pub-id></mixed-citation></ref><ref id="B73"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ryu</surname><given-names>Y. B.</given-names></name><name><surname>Jeong</surname><given-names>H. J.</given-names></name><name><surname>Kim</surname><given-names>J. H.</given-names></name><name><surname>Kim</surname><given-names>Y. M.</given-names></name><name><surname>Park</surname><given-names>J. Y.</given-names></name><name><surname>Kim</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Biflavonoids from Torreya nucifera displaying SARS-CoV 3CLpro inhibition</article-title>. <source>Bioorg. Med. Chem.</source>
<volume>18</volume> (<issue>22</issue>), <fpage>7940</fpage>&#x02013;<lpage>7947</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmc.2010.09.035</pub-id>
<pub-id pub-id-type="pmid">20934345</pub-id></mixed-citation></ref><ref id="B74"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sadat-Hosseini</surname><given-names>M.</given-names></name><name><surname>Farajpour</surname><given-names>M.</given-names></name><name><surname>Boroomand</surname><given-names>N.</given-names></name><name><surname>Solaimani-Sardou</surname><given-names>F.</given-names></name></person-group> (<year>2017</year>). <article-title>Ethnopharmacological studies of indigenous medicinal plants in the south of Kerman, Iran</article-title>. <source>J. Ethnopharmacol.</source>
<volume>199</volume>, <fpage>194</fpage>&#x02013;<lpage>204</lpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2017.02.006</pub-id>
<pub-id pub-id-type="pmid">28167292</pub-id></mixed-citation></ref><ref id="B75"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schlagenhauf</surname><given-names>P.</given-names></name><name><surname>Grobusch</surname><given-names>M. P.</given-names></name><name><surname>Maier</surname><given-names>J. D.</given-names></name><name><surname>Gautret</surname><given-names>P.</given-names></name></person-group> (<year>2020</year>). <article-title>Repurposing antimalarials and other drugs for COVID-19</article-title>. <source>Trav. Med. Infect. Dis.</source>
<volume>34</volume>, <fpage>101658</fpage>. &#x000a0;<pub-id pub-id-type="doi">10.1016/j.tmaid.2020.101658</pub-id>
</mixed-citation></ref><ref id="B76"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sharifi</surname><given-names>N.</given-names></name><name><surname>Souri</surname><given-names>E.</given-names></name><name><surname>Ziai</surname><given-names>S. A.</given-names></name><name><surname>Amin</surname><given-names>G.</given-names></name><name><surname>Amanlou</surname><given-names>M.</given-names></name></person-group> (<year>2013</year>). <article-title>Discovery of new angiotensin converting enzyme (ACE) inhibitors from medicinal plants to treat hypertension using an in vitro assay</article-title>. <source>Daru</source>
<volume>21</volume> (<issue>1</issue>), <fpage>74</fpage>. <pub-id pub-id-type="doi">10.1186/2008-2231-21-74</pub-id>
<pub-id pub-id-type="pmid">24359711</pub-id></mixed-citation></ref><ref id="B77"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shi</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>N.</given-names></name><name><surname>Li</surname><given-names>F. F.</given-names></name><name><surname>You</surname><given-names>Y. L.</given-names></name><name><surname>Wang</surname><given-names>S. Q.</given-names></name></person-group> (<year>2020</year>). <article-title>The effect of polysaccharides from Cibotium barometz on enhancing temozolomide&#x02013;induced glutathione exhausted in human glioblastoma U87 cells, as revealed by 1H NMR metabolomics analysis</article-title>. <source>Int. J. Biol. Macromol.</source>
<volume>156</volume>, <fpage>471</fpage>&#x02013;<lpage>484</lpage>. &#x000a0;<pub-id pub-id-type="doi">10.1016/j.ijbiomac.2020.03.243</pub-id>
<pub-id pub-id-type="pmid">32243933</pub-id></mixed-citation></ref><ref id="B78"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sigrist</surname><given-names>C. J.</given-names></name><name><surname>Bridge</surname><given-names>A.</given-names></name><name><surname>Le Mercier</surname><given-names>P.</given-names></name></person-group> (<year>2020</year>). <article-title>A potential role for integrins in host cell entry by SARS-CoV-2</article-title>. <source>Antivir. Res.</source>
<volume>177</volume>, <fpage>104759</fpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2020.104759</pub-id>
<pub-id pub-id-type="pmid">32130973</pub-id></mixed-citation></ref><ref id="B79"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Smit</surname><given-names>C.</given-names></name><name><surname>Peeters</surname><given-names>M. Y. M.</given-names></name><name><surname>van den Anker</surname><given-names>J. N.</given-names></name><name><surname>Knibee</surname><given-names>C. A.</given-names></name></person-group> (<year>2020</year>). <article-title>Chloroquine for SARS-CoV-2: Implications of Its Unique Pharmacokinetic and Safety Properties</article-title>. <source>Clin. Pharmacokinet.</source>
<volume>59</volume>, <fpage>659</fpage>&#x02013;<lpage>669</lpage>. <pub-id pub-id-type="doi">10.1007/s40262-020-00891-1</pub-id>
<pub-id pub-id-type="pmid">32306288</pub-id></mixed-citation></ref><ref id="B80"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Song</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>F.</given-names></name><name><surname>Tang</surname><given-names>S.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Gao</surname><given-names>Y.</given-names></name><name><surname>Lu</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>A module analysis approach to investigate molecular mechanism of TCM formula: a trial on shu-feng-jie-du formula</article-title>. <source>Evid-Based Compl. Alt. Med.</source>
<volume>2013</volume>, <fpage>1</fpage>&#x02013;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1155/2013/731370</pub-id>
</mixed-citation></ref><ref id="B81"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Song</surname><given-names>Y. H.</given-names></name><name><surname>Kim</surname><given-names>D. W.</given-names></name><name><surname>Curtis-Long</surname><given-names>M. J.</given-names></name><name><surname>Yuk</surname><given-names>H. J.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Zhuang</surname><given-names>N.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Papain-like protease (PLpro) inhibitory effects of cinnamic amides from Tribulus terrestris fruits</article-title>. <source>Biol. Pharm. Bull.</source>
<volume>37</volume> (<issue>6</issue>), <fpage>1021</fpage>&#x02013;<lpage>1028</lpage>. <pub-id pub-id-type="doi">10.1248/bpb.b14-00026</pub-id>
<pub-id pub-id-type="pmid">24882413</pub-id></mixed-citation></ref><ref id="B82"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tayel</surname><given-names>A. A.</given-names></name><name><surname>El-Sedfy</surname><given-names>M. A.</given-names></name><name><surname>Ibrahim</surname><given-names>A.</given-names><suffix>II</suffix></name><name><surname>Moussa</surname><given-names>S. H.</given-names></name></person-group> (<year>2018</year>). <article-title>Application of Quercus infectoria extract as a natural antimicrobial agent for chicken egg decontamination</article-title>. <source>Rev. Argent. Microbiol.</source>
<volume>50</volume> (<issue>4</issue>), <fpage>391</fpage>&#x02013;<lpage>397</lpage>. <pub-id pub-id-type="doi">10.1016/j.ram.2017.12.003</pub-id>
<pub-id pub-id-type="pmid">29691109</pub-id></mixed-citation></ref><ref id="B83"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tian</surname><given-names>C.</given-names></name><name><surname>Chang</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Guo</surname><given-names>Y.</given-names></name><name><surname>Lan</surname><given-names>Z.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Anti-inflammatory activity in vitro, extractive process and HPLC-MS characterization of total saponins extract from Tribulus terrestris L. fruits</article-title>. <source>Ind. Crops Prod.</source>
<volume>150</volume>, <fpage>112343</fpage>. <pub-id pub-id-type="doi">10.1016/j.indcrop.2020.112343</pub-id>
</mixed-citation></ref><ref id="B84"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Walls</surname><given-names>A. C.</given-names></name><name><surname>Park</surname><given-names>Y. J.</given-names></name><name><surname>Tortorici</surname><given-names>M. A.</given-names></name><name><surname>Wall</surname><given-names>A.</given-names></name><name><surname>McGuire</surname><given-names>A. T.</given-names></name><name><surname>Veesler</surname><given-names>D.</given-names></name></person-group> (<year>2020</year>). <article-title>Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein</article-title>. <source>Cell</source>
<volume>181</volume> (<issue>2</issue>), <fpage>281</fpage>&#x02013;<lpage>292</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2020.02.058</pub-id>
<pub-id pub-id-type="pmid">32155444</pub-id></mixed-citation></ref><ref id="B85"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wan</surname><given-names>S.</given-names></name><name><surname>Xiang</surname><given-names>Y.</given-names></name><name><surname>Fang</surname><given-names>W.</given-names></name><name><surname>Zheng</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>B.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Clinical Features and Treatment of COVID-19 Patients in Northeast Chongqing</article-title>. <source>J. Med. Virol.</source>
<volume>10</volume>, <fpage>1002</fpage>. <pub-id pub-id-type="doi">10.1002/jmv.25783</pub-id>
</mixed-citation></ref><ref id="B86"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>C. H.</given-names></name><name><surname>Zhong</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>J. P.</given-names></name><name><surname>Wang</surname><given-names>Y. F.</given-names></name><name><surname>Jia</surname><given-names>W. N.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>A network analysis of the Chinese medicine Lianhua-Qingwen formula to identify its main effective components</article-title>. <source>Mol. Syst. Biol.</source>
<volume>12</volume> (<issue>2</issue>), <fpage>606</fpage>&#x02013;<lpage>613</lpage>. <pub-id pub-id-type="doi">10.1039/C5MB00448A</pub-id>
</mixed-citation></ref><ref id="B87"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Lu</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>F.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name></person-group> (<year>2020</year>). <article-title>Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment</article-title>. <source>Biosci. Trends</source>
<volume>14</volume> (<issue>1</issue>), <fpage>64</fpage>&#x02013;<lpage>68</lpage>. <pub-id pub-id-type="doi">10.5582/bst.2020.01030</pub-id>
<pub-id pub-id-type="pmid">32037389</pub-id></mixed-citation></ref><ref id="B88"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wei</surname><given-names>T.</given-names></name><name><surname>Deng</surname><given-names>K.</given-names></name><name><surname>Gao</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Song</surname><given-names>W.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>SmKSL overexpression combined with elicitor treatment enhances tanshinone production from Salvia miltiorrhiza hairy roots</article-title>. <source>Biochem. Engin. J.</source>
<volume>158</volume>, <fpage>107562</fpage>. <pub-id pub-id-type="doi">10.1016/j.bej.2020.107562</pub-id>
</mixed-citation></ref><ref id="B89"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wen</surname><given-names>C. C.</given-names></name><name><surname>Shyur</surname><given-names>L. F.</given-names></name><name><surname>Jan</surname><given-names>J. T.</given-names></name><name><surname>Liang</surname><given-names>P. H.</given-names></name><name><surname>Kuo</surname><given-names>C. J.</given-names></name><name><surname>Arulselvan</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Traditional Chinese medicine herbal extracts of Cibotium barometz, Gentiana scabra, Dioscorea batatas, Cassia tora, and Taxillus chinensis inhibit SARS-CoV replication</article-title>. <source>J. Trad. Compl. Med.</source>
<volume>1</volume> (<issue>1</issue>), <fpage>41</fpage>&#x02013;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1016/S2225-4110(16)30055-4</pub-id>
</mixed-citation></ref><ref id="B90"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Weng</surname><given-names>J. R.</given-names></name><name><surname>Lin</surname><given-names>C. S.</given-names></name><name><surname>Lai</surname><given-names>H. C.</given-names></name><name><surname>Lin</surname><given-names>Y. P.</given-names></name><name><surname>Wang</surname><given-names>C. Y.</given-names></name><name><surname>Tsai</surname><given-names>Y. C.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Antiviral activity of Sambucus FormosanaNakai ethanol extract and related phenolic acid constituents against human coronavirus NL63</article-title>. <source>Virus Res.</source>
<volume>273</volume>, <fpage>197767</fpage>. <pub-id pub-id-type="doi">10.1016/j.virusres.2019.197767</pub-id>
<pub-id pub-id-type="pmid">31560964</pub-id></mixed-citation></ref><ref id="B91"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wong</surname><given-names>L. Y.</given-names></name><name><surname>Lui</surname><given-names>P. Y.</given-names></name><name><surname>Jin</surname><given-names>D. Y.</given-names></name></person-group> (<year>2016</year>). <article-title>A molecular arms race between host innate antiviral response and emerging human coronaviruses</article-title>. <source>Virol. Sin.</source>
<volume>31</volume> (<issue>1</issue>), <fpage>12</fpage>&#x02013;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1007/s12250-015-3683-3</pub-id>
<pub-id pub-id-type="pmid">26786772</pub-id></mixed-citation></ref><ref id="B92"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wrapp</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>N.</given-names></name><name><surname>Corbett</surname><given-names>K. S.</given-names></name><name><surname>Goldsmith</surname><given-names>J. A.</given-names></name><name><surname>Hsieh</surname><given-names>C. L.</given-names></name><name><surname>Abiona</surname><given-names>O.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Cryo-EM structure of the COVID-19 spike in the prefusion conformation</article-title>. <source>Science</source>
<volume>367</volume>, <fpage>1260</fpage>&#x02013;<lpage>1263</lpage>. <pub-id pub-id-type="doi">10.1126/science.abb2507</pub-id>
<pub-id pub-id-type="pmid">32075877</pub-id></mixed-citation></ref><ref id="B93"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wu</surname><given-names>Q.</given-names></name><name><surname>Yang</surname><given-names>X. W.</given-names></name></person-group> (<year>2009</year>). <article-title>The constituents of Cibotium barometz and their permeability in the human Caco-2 monolayer cell model</article-title>. <source>J. Ethnopharmacol.</source>
<volume>125</volume> (<issue>3</issue>), <fpage>417</fpage>&#x02013;<lpage>422</lpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2009.07.017</pub-id>
<pub-id pub-id-type="pmid">19635547</pub-id></mixed-citation></ref><ref id="B94"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xia</surname><given-names>R.</given-names></name><name><surname>Hu</surname><given-names>X.</given-names></name><name><surname>Fei</surname><given-names>Y.</given-names></name><name><surname>Willcox</surname><given-names>M.</given-names></name><name><surname>Wen</surname><given-names>L. Z.</given-names></name><name><surname>Yu</surname><given-names>M. K.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Shufeng Jiedu capsules for treating acute exacerbations of chronic obstructive pulmonary disease: a systematic review and meta-analysis</article-title>. <source>BMC Complement. Med. Ther.</source>
<volume>20</volume>, <fpage>151</fpage>. &#x000a0;<pub-id pub-id-type="doi">10.1186/s12906-020-02924-5</pub-id>
<pub-id pub-id-type="pmid">32448238</pub-id></mixed-citation></ref><ref id="B95"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xu</surname><given-names>D.</given-names></name><name><surname>Lin</surname><given-names>T. H.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Da</surname><given-names>J.</given-names></name><name><surname>Wen</surname><given-names>X. Q.</given-names></name><name><surname>Ding</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Cryptotanshinone suppresses androgen receptor-mediated growth in androgen dependent and castration resistant prostate cancer cells</article-title>. <source>Cancer Lett.</source>
<volume>316</volume> (<issue>1</issue>), <fpage>11</fpage>&#x02013;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1016/j.canlet.2011.10.006</pub-id>
<pub-id pub-id-type="pmid">22154085</pub-id></mixed-citation></ref><ref id="B96"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xu</surname><given-names>K.</given-names></name><name><surname>Cai</surname><given-names>H.</given-names></name><name><surname>Shen</surname><given-names>Y.</given-names></name><name><surname>Ni</surname><given-names>Q.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Hu</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Management of Corona Virus disease-19 (COVID-19): The Zhejiang Experience</article-title>. <source>J. Zhejiang Univ. Med. Sci.</source>
<volume>49</volume> (<issue>1</issue>), <fpage>0</fpage>.</mixed-citation></ref><ref id="B97"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Zhao</surname><given-names>S.</given-names></name><name><surname>Teng</surname><given-names>T.</given-names></name><name><surname>Abdalla</surname><given-names>A. E.</given-names></name><name><surname>Zhu</surname><given-names>W.</given-names></name><name><surname>Xie</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Systematic Comparison of Two Animal-to-Human Transmitted Human Coronaviruses: SARS-CoV-2 and SARS-CoV</article-title>. <source>Virus</source>
<volume>12</volume> (<issue>2</issue>), <fpage>244</fpage>. &#x000a0;<pub-id pub-id-type="doi">10.3390/v12020244</pub-id>
</mixed-citation></ref><ref id="B98"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>B.</given-names></name><name><surname>Kim</surname><given-names>S.</given-names></name><name><surname>Kim</surname><given-names>J. H.</given-names></name><name><surname>Lim</surname><given-names>C.</given-names></name><name><surname>Kim</surname><given-names>H.</given-names></name><name><surname>Cho</surname><given-names>S.</given-names></name></person-group> (<year>2019</year>). <article-title>Gentiana scabra Bunge roots alleviates skin lesions of contact dermatitis in mice</article-title>. <source>J. Ethnopharmacol.</source>
<volume>233</volume>, <fpage>141</fpage>&#x02013;<lpage>147</lpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2018.12.046</pub-id>
<pub-id pub-id-type="pmid">30630090</pub-id></mixed-citation></ref><ref id="B99"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Islam</surname><given-names>M. S.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name></person-group> (<year>2020</year>). <article-title>Traditional Chinese Medicine in the Treatment of Patients Infected with 2019-New Coronavirus (SARS-CoV-2CoV-2): A Review and Perspective</article-title>. <source>Int. J. Biol. Sci.</source>
<volume>16</volume> (<issue>10</issue>), <fpage>1708</fpage>. <pub-id pub-id-type="doi">10.7150/ijbs.45538</pub-id>
<pub-id pub-id-type="pmid">32226288</pub-id></mixed-citation></ref><ref id="B100"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Yu</surname><given-names>Y.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name></person-group> (<year>2020</year>). <article-title>Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study</article-title>. <source>Lancet Respir. Med.</source>
<volume>8</volume> (<issue>5</issue>), <fpage>475</fpage>&#x02013;<lpage>481</lpage>. <pub-id pub-id-type="doi">10.1016/S2213-2600(20)30079-5</pub-id>
<pub-id pub-id-type="pmid">32105632</pub-id></mixed-citation></ref><ref id="B101"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yu</surname><given-names>M. S.</given-names></name><name><surname>Lee</surname><given-names>J.</given-names></name><name><surname>Lee</surname><given-names>J. M.</given-names></name><name><surname>Kim</surname><given-names>Y.</given-names></name><name><surname>Chin</surname><given-names>Y. W.</given-names></name><name><surname>Jee</surname><given-names>J. G.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Identification of myricetin and scutellarein as novel chemical inhibitors of the SARS coronavirus helicase, nsP13</article-title>. <source>Bioorg. Med. Chem. Lett.</source>
<volume>22</volume> (<issue>12</issue>), <fpage>4049</fpage>&#x02013;<lpage>4054</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmcl.2012.04.081</pub-id>
<pub-id pub-id-type="pmid">22578462</pub-id></mixed-citation></ref><ref id="B102"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yuan</surname><given-names>L.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Song</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>S.</given-names></name><name><surname>Tian</surname><given-names>C.</given-names></name><name><surname>Xing</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>p53 degradation by a coronavirus papain-like protease suppresses type I interferon signaling</article-title>. <source>J. Biol. Chem.</source>
<volume>290</volume>, <fpage>3172</fpage>&#x02013;<lpage>3182</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M114.619890</pub-id>
<pub-id pub-id-type="pmid">25505178</pub-id></mixed-citation></ref><ref id="B103"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yun</surname><given-names>J. W.</given-names></name><name><surname>Kim</surname><given-names>S. H.</given-names></name><name><surname>Kim</surname><given-names>Y. S.</given-names></name><name><surname>You</surname><given-names>J. R.</given-names></name><name><surname>Cho</surname><given-names>E. Y.</given-names></name><name><surname>Yoon</surname><given-names>J. H.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Enzymatic extract from Ecklonia cava: Acute and subchronic oral toxicity and genotoxicity studies</article-title>. <source>Regulat. Toxicol. Pharmacol.</source>
<volume>92</volume>, <fpage>46</fpage>&#x02013;<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1016/j.yrtph.2017.10.034</pub-id>
</mixed-citation></ref><ref id="B104"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>T.</given-names></name><name><surname>Zhu</surname><given-names>M.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Bi</surname><given-names>K.</given-names></name></person-group> (<year>2010</year>). <article-title>Simultaneous analysis of seven bioactive compounds in Sambucus chinensis Lindl by HPLC</article-title>. <source>Annalyt. Lett.</source>
<volume>43</volume>, <fpage>2525</fpage>&#x02013;<lpage>2533</lpage>. <pub-id pub-id-type="doi">10.1080/00032711003731399</pub-id>
</mixed-citation></ref><ref id="B105"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>T.</given-names></name><name><surname>Wu</surname><given-names>Q.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name></person-group> (<year>2020</year>). <article-title>Probable pangolin origin of SARS-CoV-2CoV-2 associated with the COVID-19 outbreak</article-title>. <source>Curr. Biol.</source>
<volume>30</volume>, <fpage>1</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.cub.2020.03.022</pub-id>
<pub-id pub-id-type="pmid">31839447</pub-id></mixed-citation></ref><ref id="B106"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J. J.</given-names></name><name><surname>Dong</surname><given-names>X.</given-names></name><name><surname>Cao</surname><given-names>Y. Y.</given-names></name></person-group> (<year>2020</year>). <article-title>Clinical characteristics of 140 patients infected by SARS-CoV-2 in Wuhan, China</article-title>. <source>Allergy.</source>
<volume>75</volume> (<issue>7</issue>), <fpage>1730</fpage>&#x02013;<lpage>1741</lpage>. &#x000a0;<pub-id pub-id-type="doi">10.1111/all.14238</pub-id>
<pub-id pub-id-type="pmid">32077115</pub-id></mixed-citation></ref><ref id="B107"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Lin</surname><given-names>D.</given-names></name><name><surname>Sun</surname><given-names>X.</given-names></name><name><surname>Curth</surname><given-names>U.</given-names></name><name><surname>Drosten</surname><given-names>C.</given-names></name><name><surname>Sauerhering</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Crystal structure of SARS-CoV-2main protease provides a basis for design of improved &#x003b1;-ketoamide inhibitors</article-title>. <source>Science</source>
<volume>368</volume> (<issue>6489</issue>), <fpage>409</fpage>&#x02013;<lpage>412</lpage>. <pub-id pub-id-type="doi">10.1126/science.abb3405</pub-id>
<pub-id pub-id-type="pmid">32198291</pub-id></mixed-citation></ref><ref id="B108"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhou</surname><given-names>P.</given-names></name><name><surname>Yang</surname><given-names>X. L.</given-names></name><name><surname>Wang</surname><given-names>X. G.</given-names></name><name><surname>Hu</surname><given-names>B.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>A pneumonia outbreak associated with a new coronavirus of probable bat origin</article-title>. <source>Nature</source>
<volume>579</volume>, <fpage>270</fpage>&#x02013;<lpage>273</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-020-2012-7</pub-id>
<pub-id pub-id-type="pmid">32015507</pub-id></mixed-citation></ref><ref id="B109"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhu</surname><given-names>G.</given-names></name><name><surname>Luo</surname><given-names>Y.</given-names></name><name><surname>Xu</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Zhu</surname><given-names>M.</given-names></name></person-group> (<year>2019</year>). <article-title>Anti-diabetic compounds from the seeds of Psoralea corylifolia</article-title>. <source>Fitoterapia</source>
<volume>139</volume>, <fpage>104373</fpage>. <pub-id pub-id-type="doi">10.1016/j.fitote.2019.104373</pub-id>
<pub-id pub-id-type="pmid">31629053</pub-id></mixed-citation></ref></ref-list></back></article>